Visit our Location
11860 Vista Del Sol Dr Suite 105,
El Paso, TX 79936
Give us a Call
+1 (915) 412-6680
Send us a Message
[email protected]
Opening Hours
Mon-Thu: 7 AM - 7 PM
Fri - Sun: Closed

Category: Progesterone Support for Calm, Sleep, and Hormone Balance

ChiroMedBlogBioidentical Hormone Replacement Therapy in El Paso, TXProgesterone Support for Calm, Sleep, and Hormone Balance

Progesterone is often called the calming hormone because it helps support restful sleep, emotional balance, menstrual health, and a healthy relationship with estrogen. Low progesterone may contribute to irritability, anxiety, poor sleep, irregular cycles, heavy periods, and symptoms related to hormonal imbalance. The role of progesterone in overall wellness and reviews natural, medical, and integrative approaches used to support progesterone balance.

Bioidentical Hormones Benefits Overview for Patient Wellness


Transform your health with bioidentical hormones and elevate patient wellness through natural hormonal balance.

Navigating Hormonal Health: An Integrative Approach to Wellness

In this educational post, I will explore the complex and fascinating world of hormone optimization from an integrative perspective. Drawing upon the latest evidence-based research and my clinical experience, we will delve into the nuances of hormone replacement therapy (HRT), including the transition from traditional birth control to bioidentical hormones. We will discuss the physiological basis for common symptoms like menstrual migraines and perimenopausal anxiety, and I’ll share specific protocols for managing these conditions effectively. Furthermore, we will examine the crucial role of nutrition, sleep, and targeted supplementation in supporting hormonal balance. This discussion will also cover advanced testing methodologies and address common concerns, such as the use of topical estrogens and the safety of HRT in various patient populations. Finally, I will explain how integrative chiropractic care is an essential component of this holistic treatment model, helping to restore overall physiological function and enhance the body’s innate healing capabilities.

Foundations of Bioidentical Hormone Replacement: Source and Application

As a practitioner dedicated to functional and integrative medicine, I frequently encounter a question from both patients and fellow clinicians about the origins of the hormones we use. Specifically, “What is the source of the bioidentical hormones, like estrogen, used in therapy?”
This is a fantastic and crucial question. The bioidentical estradiol and progesterone we use in compounded therapies are derived from plant sources. The starting molecule, diosgenin, is extracted from wild yams. It is important to note that this is not the sweet potato but the true yam plant. Diosgenin is a phytosteroid, a plant-based steroid, with a molecular structure that makes it an ideal precursor. In a compounding pharmacy, skilled chemists modify this diosgenin molecule, altering its chemical structure to create 17-beta estradiol and progesterone. These resulting hormones are termed “bioidentical” because they are molecularly identical to the hormones our bodies produce naturally. This molecular mimicry is key to their efficacy and safety profile, as the body’s cellular receptors recognize and utilize them just as they would endogenous hormones.
Historically, some hormone precursors were derived from soy, but the industry has largely shifted to yam-based sources to avoid potential issues related to soy sensitivities and phytoestrogenic effects.
Another common clinical question is about layering different types of therapies. For instance, can a topical cream for enhancing libido be used in conjunction with hormone pellets?

  • Yes, absolutely. You can layer these therapies. A topical cream, which might contain a blend of ingredients such as testosterone, oxytocin, or other compounds designed to increase local blood flow and nerve sensitivity, works through a different mechanism and pathway than systemic hormone pellets do.
  • The pellets provide a steady, baseline level of hormones (like testosterone and estradiol) systemically, which addresses the root cause of low libido from a physiological standpoint.
  • The topical cream provides targeted, localized support. Because it’s utilized differently, there’s no contraindication; in fact, this multimodal approach can be highly effective for patients with refractory libido issues.


Navigating the Transition from Birth Control to BHRT

A significant part of my practice involves helping women transition from synthetic hormonal birth control to bioidentical hormone replacement therapy (BHRT). The conventional practice of keeping women on birth control pills until age 51 and then abruptly stopping is outdated and, frankly, unsafe.

The Risks of Prolonged Oral Contraceptive Use

Birth control pills are designed for one primary purpose: contraception. Once a woman no longer requires them for preventing pregnancy—perhaps due to a tubal ligation, having an IUD, or a vasectomized partner—she should not remain on them for other reasons like managing menstrual migraines or endometriosis. Synthetic hormones in oral contraceptives carry significant risks, including:

  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism (PE)
  • Stroke

In my clinical practice and from collaborating with my colleagues, I have seen devastating cases of women in their 40s with no other underlying health issues suffering major strokes directly linked to their oral contraceptive use. While the risk-benefit ratio may be acceptable for a 20-year-old (where the risk of a DVT from pregnancy is comparable to the risk from the pill), this ratio shifts dramatically as a woman ages and no longer faces the risk of pregnancy.

The Transition Protocol

So, how do we safely transition a patient? The key is to determine her true menopausal status, which is masked by the synthetic hormones in birth control pills.

  1. Initial Bloodwork: I start by testing the Follicle-Stimulating Hormone (FSH) level while the patient is still on the pill.
    • An FSH of 10 mIU/mL or greater strongly suggests she is in the menopausal transition.
    • An FSH of 5 mIU/mL or less indicates she is likely still premenopausal.
  2. The “Gray Zone”: If the FSH falls into the intermediate range (e.g., 6-9 mIU/mL), clarity is needed. I will have the patient stop the birth control pill for approximately three weeks. During this washout period, it’s crucial to use a reliable barrier method of contraception, like condoms.
  3. Confirmatory Testing: After the three-week washout, I retest the FSH. A level of 23 mIU/mL or higher is a definitive indicator of menopause.
  4. Seamless Transition: Once menopause is confirmed, the transition can happen literally overnight. She stops the pill and begins her personalized BHRT protocol, which typically includes bioidentical estrogen and testosterone (often via pellets) and oral micronized progesterone at bedtime.

For a perimenopausal patient, meaning she hasn’t been without a cycle for a full 12 months, a more cautious approach is warranted. I would start with a lower dose of estrogen, such as 6 mg, to avoid inducing bleeding. We can always titrate the dose upwards based on her symptoms and follow-up lab work in six weeks. It’s always easier to add more hormone than to deal with the consequences of overdosing.

The Critical Role of Integrative Chiropractic Care

In my practice, where I hold credentials as both a chiropractic physician and an advanced practice nurse, I have observed the profound impact of combining hormonal and metabolic treatments with physical medicine. Integrative chiropractic care is not just about addressing back pain; it is a foundational element of restoring systemic health.
The nervous system is the master controller of the body, directly influencing the endocrine system via the hypothalamic-pituitary-adrenal (HPA) axis. Structural misalignments in the spine, known as vertebral subluxations, can create nerve interference, disrupting the delicate communication between the brain and the body’s glands, including the ovaries, adrenals, and thyroid.

  • Restoring Neurological Function: Chiropractic adjustments correct these subluxations, reducing nerve interference and optimizing HPA axis function. This can help normalize cortisol production, which in turn reduces the “theft” of pregnenolone (the mother hormone) for cortisol synthesis, leaving more available to produce progesterone and other vital sex hormones.
  • Improving Blood Flow: Adjustments improve circulation to the pelvic organs and endocrine glands, ensuring they receive the oxygen and nutrients needed for optimal function.
  • Reducing Systemic Stress: The physical act of a chiropractic adjustment has been shown to decrease sympathetic (fight-or-flight) tone and increase parasympathetic (rest-and-digest) activity. This physiological shift is crucial for hormonal balance, as chronic stress is a major disruptor of the endocrine system.

By integrating chiropractic care, we are not just treating symptoms; we are addressing the underlying structural and neurological dysfunctions that contribute to hormonal imbalance, thereby creating a more robust and lasting foundation for wellness.


Addressing Specific Conditions: Anxiety, Migraines, and Sleep

Perimenopausal Anxiety and PMS

Severe anxiety and mood swings, particularly those linked to the menstrual cycle (PMS/PMDD), are often rooted in hormone fluctuations. While testosterone replacement is a cornerstone for mood stabilization, oral micronized progesterone is a powerful tool, especially for anxiety.
Progesterone’s calming effect comes from its metabolite, allopregnanolone, which acts as a positive allosteric modulator of the GABA-A receptor in the brain. GABA is the primary inhibitory neurotransmitter, and enhancing its function promotes relaxation and reduces anxiety.

  • Nighttime Dosing: For sleep disturbances and generalized anxiety, I typically prescribe oral progesterone at bedtime.
  • Daytime Anxiety: For patients with severe daytime anxiety, a small dose of 25 mg of oral progesterone can be remarkably effective. I have seen this strategy transform the lives of patients, including young women in their teens with debilitating hormonal fluctuations, allowing them to avoid psychiatric medications.


Menstrual Migraines

Menstrual migraines are triggered by the sharp drop in estrogen that occurs right before the onset of menses. The treatment is elegantly simple and highly effective.

  • The Protocol: I prescribe a very low dose of topical estrogen (e.g., a small dab of estradiol cream) to be applied daily for the seven days leading up to the expected start of the period.
  • The Mechanism: This small amount of estrogen is just enough to create a “trough” level, preventing the precipitous drop that triggers the migraine cascade. It’s a drop in the bucket in terms of total monthly estrogen exposure and is not enough to disrupt the natural cycle or require opposing progesterone. This simple intervention has a success rate of over 95% in my clinical experience.

Sleep, Growth Hormone, and the Modern Epidemic

Sleep is non-negotiable for hormonal health. The most critical period for hormone production is between 11:00 PM and 2:00 AM. During this deep sleep window, the body produces growth hormone (GH), which in turn stimulates the liver to produce Insulin-like Growth Factor 1 (IGF-1).
I see a concerning trend in younger patients. They are staying up until 2:00 AM on their phones, bathed in blue light that suppresses melatonin production. This lifestyle completely obliterates their deep sleep cycle. Consequently, they are not producing adequate growth hormone, their IGF-1 levels are collapsing, and their entire hormonal cascade suffers. This is often compounded by a diet high in sugar and processed foods. The result is a generation of young people with the hormonal profiles of much older individuals.
My approach involves a comprehensive lifestyle overhaul:

  • Dietary Intervention: An organic, whole-foods diet, eliminating sugar and processed foods.
  • Supplementation: A targeted regimen including a high-quality B-complex, Vitamin D, iodine, and probiotics.
  • Sleep Hygiene: Strict sleep schedules and eliminating screen time before bed.
  • Chiropractic Care: To reduce systemic stress and improve neurological function.


Advanced Topics and Clinical Pearls

Topical Estrogen on the Face

Some patients ask about using topical estrogen on their faces for cosmetic benefits. While estrogen does improve skin elasticity and collagen production, applying a standard BHRT estrogen cream directly to the face is problematic. The facial skin is highly vascular, and this application would lead to significant systemic absorption, driving serum estrogen levels dangerously high. A much safer alternative is to use a compounded cream containing estriol (E3), the weakest of the three main estrogens, which provides local benefits with minimal systemic absorption.

Testing and Monitoring

Accurate testing is paramount. For thyroid hormones, I prefer using Liquid Chromatography-Mass Spectrometry (LC-MS). It is more precise than radioimmunoassay (RIA), which can be subject to cross-reactivity with substances like biotin, leading to falsely elevated estradiol results. When testing T3, it’s essential to know when the patient took their last dose of thyroid medication, as a recent dose can cause a transient spike in levels.

Interacting with Other Medical Professionals

Unfortunately, there can be resistance from practitioners in other specialties, such as oncology or cardiology, who may not be up to date with the literature on BHRT. The best approach is education and providing data. Dr. Rebecca Glaser, a leading researcher, has an excellent open-access website that collates studies on the safety of testosterone therapy, even in breast cancer survivors. Providing this evidence-based literature to concerned colleagues can help bridge the knowledge gap and ensure continuity of care for our patients.
Hormone optimization is a journey that requires a personalized, evidence-based, and integrative approach. By addressing the biochemical, structural, and lifestyle factors that influence hormonal health and by using tools like BHRT and integrative chiropractic care, we can empower our patients not just to manage symptoms but to achieve true vitality and wellness.

References


SEO Tags: bioidentical hormones, integrative chiropractic, hormone replacement therapy, Dr. Alexander Jimenez, BHRT, perimenopause, menopause, testosterone therapy, oral progesterone, menstrual migraines, FSH testing, transitioning from birth control, functional medicine, HPA axis, vertebral subluxation, estriol, sleep and hormones

Clinical Hormone Protocols and Chiropractic Support

Clinical Hormone Protocols and Chiropractic Support

Clinical Hormone Protocols and Chiropractic Support
A woman is in a consultation with a doctor in a clinic.

Abstract

In this educational post, I present a clear, first-person journey through modern, evidence-based approaches to common hormonal and metabolic challenges I see in practice: iron deficiency and heavy menstrual bleeding, PCOS management, post–gastric bypass considerations, testosterone therapy physiology, contraception risk-benefit decisions in midlife, SHBG-related treatment resistance, and progesterone strategy in premenopause, perimenopause, and menopause. I integrate clinical observations from my work as a chiropractor and advanced practice clinician and show how integrative chiropractic care fits within comprehensive, patient-centered protocols. I highlight practical dosing frameworks, explain underlying physiology—absorption, distribution, and renal excretion—and share how to avoid pitfalls with estrogen modulation, environmental exposures, and breast cancer risk. Throughout, I reference the latest research from leading investigators, link to sources, and offer stepwise algorithms and bullet-pointed checklists you can use in clinical decision-making.

Introduction: Why Multidisciplinary Care Matters in Hormone Health

In my clinical practice, I often begin by assembling the right team around the patient—endocrinology, primary care, women’s health, nutrition, behavioral health, and integrative chiropractic—to ensure we address physiology, biomechanics, lifestyle, and safety. Many of the cases discussed below involve overlapping contributors—iron deficiency, thyroid status, insulin resistance, post-surgical malabsorption, and altered sex-hormone binding globulin (SHBG). Without a comprehensive approach, patients can remain symptomatic despite reasonable therapies.

I use a structured framework:

  • Define the primary symptom drivers: bleeding, fatigue, mood, sleep, weight, libido, and cognition.
  • Screen for common physiological disruptors: iron deficiency, thyroid dysfunction, insulin resistance, chronic inflammation, micronutrient deficiencies, gut dysbiosis.
  • Model hormone kinetics: absorption, distribution, metabolism, and excretion.
  • Map risk-benefit: contraception, vascular risk (DVT), bone health, breast cancer.
  • Layer integrative chiropractic care: neuromusculoskeletal optimization, autonomic regulation, sleep and stress coaching, movement prescriptions, and pain reduction that support endocrine balance.

Iron Deficiency, Heavy Menstrual Bleeding, and Cyclic Progesterone

Many women I see have untreated or under-treated iron deficiency. Heavy menstrual bleeding leads to cumulative iron loss, lowering ferritin and impairing oxygen delivery and mitochondrial function. That drives fatigue, brain fog, exercise intolerance, hair thinning, and altered thermoregulation.

Key physiology:

  • Iron is essential for hemoglobin, myoglobin, mitochondrial electron transport (complexes I–IV), thyroid peroxidase activity, and neurotransmitter synthesis.
  • Low ferritin (<30–50 ng/mL in symptomatic patients) is commonly associated with fatigue, even when hemoglobin remains normal.
  • Copper supports ceruloplasmin and iron mobilization from stores. Low copper can blunt iron’s efficacy.

My evidence-based approach:

  • Assess CBC, ferritin, transferrin saturation, CRP (to interpret ferritin), TSH, free T4, free T3, and B12/folate.
  • Consider cyclic progesterone to stabilize the endometrium and reduce bleeding. In premenopausal heavy bleeding, physiologic micronized progesterone can reduce flow by limiting endometrial proliferation and enhancing orderly shedding.
  • Supplement iron with a well-tolerated chelate (e.g., ferrous bisglycinate) and co-factors:
    • Vitamin C to enhance non-heme iron absorption.
    • Copper (if low), magnesium, and B vitamins to support erythropoiesis.
  • Treat thyroid dysfunction as it contributes to menorrhagia and anemia by altering clotting factors and endometrial function.
  • Use dietary strategies: heme iron sources, polyphenols timed away from iron dosing, and avoiding inhibitors (tea/coffee) around iron intake.

Why cyclic progesterone helps:

  • Progesterone counterbalances estrogen-induced endometrial proliferation.
  • It improves spiral artery stability and reduces prostaglandin-mediated hyperperistalsis and cramping.
  • Cyclic dosing aligns with the luteal phase, supporting more physiologic endometrial responses.

Clinical checklist:

  • Confirm iron deficiency (ferritin and iron studies).
  • Initiate iron plus co-factors; schedule follow-up ferritin/TSAT.
  • Use cyclic micronized progesterone for 2–3 cycles and reassess bleeding.
  • Normalize thyroid function if abnormal.
  • Integrate chiropractic care to address fatigue-related deconditioning and pelvic floor mechanics.

PCOS: Insulin Resistance, Ovulatory Dysfunction, and Progesterone Use

In PCOS, I emphasize insulin-sensitizing strategies, cycle regulation, and endometrial protection.

PCOS physiology:

  • Hyperinsulinemia raises ovarian theca cell androgen production.
  • Altered GnRH pulsatility impairs ovulation; unopposed estrogen exposes the endometrium to proliferative signals, increasing the risk of heavy bleeding.
  • SHBG is often reduced by insulin resistance, increasing free androgens and symptoms (acne, hirsutism).

My protocol:

  • Lifestyle: progressive resistance and aerobic training; sleep optimization; high-fiber, low-glycemic diet; targeted weight reduction.
  • Metabolic supports: inositol (myo- and D-chiro), magnesium, vitamin D, omega-3s; consider metformin or GLP-1 agonists when indicated.
  • Cyclic progesterone can protect the endometrium and regulate bleeding in anovulatory cycles.
  • Monitor lipids, A1c, fasting insulin, LH/FSH ratio, and ultrasound where appropriate.

Why progesterone in PCOS:

  • Provides luteal-phase coverage to reduce endometrial proliferation.
  • May improve sleep and anxiety through GABAergic modulation, supporting adherence to lifestyle changes.

My clinical observation:

  • Adding cyclic progesterone while addressing insulin resistance reduces bleeding within 2–3 cycles and improves energy as ferritin normalizes.

Post–Gastric Bypass and Malabsorption: Gut, Micronutrients, and Hormone Therapy

Post-bariatric patients present unique challenges due to altered anatomy and absorption.

Physiology considerations:

  • Reduced gastric acid and bypassed segments alter the absorption of iron, B12, folate, calcium, vitamin D, and fat-soluble vitamins.
  • Microbiome changes and small intestinal bacterial overgrowth (SIBO) can impair nutrient uptake and mucosal integrity.

My approach:

  • Aggressively test and replace micronutrients: iron, B12, folate, vitamin D, calcium, magnesium, zinc, copper, selenium, vitamins A, E, and K.
  • Use probiotics tailored for upper and lower GI support and consider prebiotics if tolerated.
  • If oral iron is poorly absorbed, consider IV iron repletion.
  • For hormone therapies:
    • Prefer transdermal routes for estrogens/progestins to bypass first-pass metabolism and variable absorption.
    • Use subcutaneous pellet or injectable strategies judiciously, titrating based on symptoms and lab response.
  • Monitor markers of inflammation and renal function since excretion pathways (for testosterone pellets) are renal-dominant.

Integrative chiropractic fit:

  • Address post-surgical biomechanics, core stability, and autonomic balance to reduce pain and improve exercise tolerance, aiding insulin sensitivity and weight maintenance.

Testosterone Therapy Physiology: Absorption, Distribution, and Renal Excretion

When optimizing testosterone, I emphasize three kinetic pillars: absorption, distribution, and excretion.

  • Absorption: For transdermals and pellets, local blood flow and cardiac output matter. Greater capillary perfusion (e.g., regular exercise) increases uptake; patients with sedentary habits may exhibit slower rises.
  • Distribution: Testosterone disperses throughout total body water and adipose compartments. Higher BMI dilutes effective concentration; weight loss reduces distribution volume, potentially increasing exposure at a given dose.
  • Excretion: Testosterone and its metabolites are predominantly renally cleared. Older adults with reduced GFR maintain levels longer; lower doses often suffice with extended duration of effect.

Clinical implications:

  • After significant weight loss (e.g., 250 lb to 190 lb), prior dosing may over-expose; re-calculate based on body composition changes.
  • Elderly males may experience prolonged pellet duration (e.g., 6–9 months) due to slower clearance—dose conservatively and extend intervals.

Managing estrogenic symptoms:

  • Transient breast tenderness in early therapy often reflects a rapid rise in testosterone with aromatization to estradiol. This typically resolves after initial titration.
  • I avoid routine estrogen blockers unless there is clear evidence of persistent symptomatic hyperestrogenism; instead, I optimize dose, timing, and route.
  • If needed, I may use targeted nutraceuticals such as diindolylmethane (DIM) to support balanced estrogen metabolism, but I prefer to correct kinetics first.

Safety and performance myths:

  • Requests for “extra sessions” to get “jacked” rapidly are unsafe and unnecessary; supraphysiologic dosing risks adverse effects and paradoxical sexual dysfunction.
  • I counsel clearly: more is not better; tailored, steady-state physiology produces superior outcomes.

Midlife Contraception, DVT Risk, and Rational Alternatives

Risk-benefit changes with age. In my practice:

  • Young adults on oral contraceptives accept a modestly increased risk of venous thromboembolism (VTE) that often remains acceptable given high contraceptive utility.
  • By ages 40–45+, for women who no longer need contraception (e.g., IUD in place or tubal ligation), continued combined oral contraceptives may present unnecessary VTE and stroke risks.

Practical steps:

  • If the goal is symptom control (PMS, dysmenorrhea, endometriosis), I prefer non-contraceptive hormone strategies: micronized progesterone, low-dose transdermal estradiol balanced with progesterone, or levonorgestrel IUD for local endometrial control.
  • I avoid systemic estrogen-progestin contraceptives in midlife when contraception is not needed.
  • Integrate SHBG dynamics in the decision: high SHBG often blunts the free testosterone response.

SHBG, Free Testosterone, and Clinical Resistance

I frequently see midlife women with high SHBG (e.g., ~115 nmol/L) who report minimal benefit until total testosterone is pushed high—an approach I generally avoid.

Physiology:

  • SHBG binds testosterone and estradiol. Higher SHBG levels reduce free fractions, leading to symptomatic “non-response” despite normal total levels.
  • Estrogen-containing contraceptives elevate SHBG; hyperthyroidism, liver disease, and genetics also contribute.

My strategy:

  • Lower SHBG is influenced by changing the hormonal milieu rather than forcing total testosterone upward.
    • Replace combined oral contraceptives with a levonorgestrel IUD to minimize systemic estrogen contribution to SHBG.
    • Address thyroid status, liver health, and insulin resistance.
  • Aim to optimize free testosterone within physiologic ranges, not inflate total values.

Clinical pearl:

  • Women with high SHBG are often difficult to satisfy symptomatically if contraceptives remain unchanged. Shifting to an IUD and carefully titrating physiological dosing improves mood, energy, libido, and reduces the risk of adverse events.

Progesterone in Premenopause vs Perimenopause and Menopause

I differentiate between contraceptive progestins and physiologic progesterone:

  • In premenopause, progestins in combined oral contraceptives primarily prevent ovulation and pregnancy; they are not designed for symptom modulation alone.
  • In perimenopause and menopause, micronized progesterone is used therapeutically to treat symptoms: sleep disturbance, anxiety, vasomotor instability, and heavy bleeding. It is bioidentical, engages GABA-A receptors, and provides endometrial protection when used with estradiol.

Why use micronized progesterone:

  • Better tolerability and neurosteroid benefits.
  • Lower thrombotic risk compared to some synthetic progestins when paired with transdermal estradiol.
  • Improves sleep architecture and reduces night sweats.

Risk considerations:

  • Certain synthetic progestins combined with oral estrogens may elevate breast cancer risk compared to regimens using transdermal estradiol plus micronized progesterone; I tailor choices based on family history, prior exposures, and current evidence.

Addressing Environmental Exposures and SHBG Modifiers

Patients often ask whether environmental toxins (e.g., lead) significantly alter SHBG or testosterone responses. My stance:

  • While some supplements claim to reduce SHBG by 10–15%, such modest shifts rarely translate to meaningful clinical benefit without changing the hormonal environment.
  • I prioritize root-cause changes: removing exogenous estrogens, stabilizing thyroid and liver function, improving metabolic health, and fine-tuning hormone dosing and route.

Pellet Dosing, Durability, and Renal Considerations

Pellet therapy can be effective when applied thoughtfully:

  • I avoid nightly “stacking” of transdermal testosterone at uniform high doses; chronic overexposure risks dysregulation and breakthrough issues.
  • For heavy bleeding cases, I may cycle a structured progesterone regimen for several months to stabilize the endometrium before introducing or escalating other therapies.
  • In elderly men, reduced renal clearance extends pellet longevity; I plan for longer intervals and lower insertions.

Erectile Dysfunction and Testosterone: Clarifying Misconceptions

I am often asked whether atrial fibrillation or cardioversion interacts adversely with testosterone. Findings suggest:

  • Men with androgen deficiency who normalize testosterone prior to certain cardiac procedures may experience improved outcomes, likely through metabolic and autonomic stabilization.
  • Erectile dysfunction (ED) is multifactorial—vascular, neurologic, and endocrine—and not inherently caused by appropriate testosterone replacement. Careful titration minimizes risks.

I emphasize:

  • Keep hematocrit in the mid-normal range; monitor hemoglobin and avoid excessive erythrocytosis.
  • Target mid-normal total and free testosterone; focus on symptom resolution and safety metrics.

Integrative Chiropractic Care: Biomechanics, Autonomic Balance, and Endocrine Support

Where does integrative chiropractic care fit in?

  • Pain relief and mobility: Reducing nociceptive input lowers the cortisol and catecholamine burden, supporting sex hormone signaling and thyroid function.
  • Autonomic regulation: Cervical and thoracic segmental work may modulate sympathetic-parasympathetic balance, improving sleep, HRV, and stress resilience.
  • Movement prescriptions: Progressive loading enhances insulin sensitivity, bone density, and capillary perfusion—improving hormone absorption and metabolic outcomes.
  • Pelvic alignment and floor function: In heavy bleeding and pelvic pain, optimizing sacral mechanics can reduce cramping and enhance lymphatic drainage, aiding symptom control.
  • Post-bariatric support: Core stabilization and low-impact aerobic plans accommodate altered biomechanics and support long-term weight maintenance.

My clinical observations from ChiroMed:

  • When we combine biomechanical optimization with iron repletion, cyclic progesterone, and metabolic therapy, women report faster improvements in energy and menstrual regularity.
  • In PCOS, structured resistance training guided by chiropractic-informed movement analysis reduces central adiposity and improves ovulatory patterns.
  • In older men on testosterone pellets, a tailored mobility program plus hydration and renal-friendly lifestyle supports steady hormone levels and minimizes adverse effects.

Stepwise Clinical Algorithms and Bullet Points

Heavy bleeding with suspected iron deficiency:

  • Screen: CBC, ferritin, TSAT, CRP, TSH, free T4, free T3.
  • Treat: iron + vitamin C; assess copper and magnesium; cyclic micronized progesterone; address thyroid dysfunction.
  • Follow: ferritin target >50–100 ng/mL depending on symptoms; re-test every 8–12 weeks.
  • Integrate: pelvic biomechanics, stress reduction, sleep support.

PCOS symptom cluster:

  • Labs: fasting insulin, A1c, lipids, LH/FSH, vitamin D; consider ultrasound.
  • Lifestyle: strength + aerobic; high-fiber diet; sleep retraining.
  • Therapy: inositol, magnesium, omega-3; consider metformin/GLP-1; cyclic progesterone for endometrial protection.
  • Chiropractic: movement coaching; pain reduction for adherence.

Post–gastric bypass:

  • Assess: iron, B12, folate, vitamins A/D/E/K, calcium, magnesium, zinc, selenium.
  • Replace: oral vs IV based on tolerance; transdermal hormones favored.
  • GI: targeted probiotics; evaluate SIBO if symptoms persist.
  • Movement: gentle progression to improve perfusion and absorption.

Testosterone optimization:

  • Kinetics: absorption (perfusion), distribution (BMI), excretion (renal).
  • Dosing: titrate after weight change; lower doses in the elderly; avoid supraphysiologic spikes.
  • Monitoring: total/free T, estradiol, hematocrit, PSA (men), symptoms.
  • Avoid routine estrogen blockers; correct underlying kinetics.

Midlife contraception:

  • Reassess need: if no pregnancy risk, minimize systemic estrogen-progestin exposure.
  • Prefer LNG-IUD for bleeding control; use physiologic hormone therapy for symptoms.
  • Consider SHBG effects and tailor accordingly.

SHBG management:

  • Identify contributors: OCPs, thyroid, liver, and insulin resistance.
  • Reduce SHBG influence by changing contraception and optimizing metabolic health.
  • Target free testosterone rather than inflating total levels.

Safety and communication:

  • Educate on risks of overdosing and myths about “extra sessions.”
  • Reinforce adherence and measured titration.
  • Use shared decision-making with transparent lab review.

Conclusion: Precision Protocols with Whole-Person Care

The strongest outcomes arise when we blend precise, physiology-based hormone protocols with integrative chiropractic care and lifestyle medicine. By correcting iron deficiency, stabilizing cycles with progesterone, respecting testosterone kinetics, and rationalizing contraception choices in midlife, we reduce risk and improve quality of life. Each intervention is chosen for a physiologic reason and is tested against symptoms and labs. With careful monitoring and team-based care, patients can achieve durable, meaningful improvements.

References

Personalized Hormone Optimization and Health Support

Personalized Hormone Optimization and Health Support

Personalized Hormone Optimization and Health Support

Abstract

In this educational post, I share my integrative, evidence-based approach to optimizing hormones for women and men—focusing on how declines in testosterone, estradiol, and progesterone can drive anxiety, irritability, sleep fragmentation, low libido, metabolic resistance, and chronic pain. I explain the physiology behind these symptoms, how I layer therapies to honor receptor sensitivity and avoid side effects, and how to select the right route—pellets, injections, patches, creams/gels, or sublingual—based on your goals and biology. I also show how integrative chiropractic care supports autonomic balance, neuromuscular health, and inflammation control, thereby enhancing hormone therapy outcomes. Throughout, I highlight current findings from leading researchers and share clinical observations from my practice to provide you with a clear, practical roadmap you can use with your care team.

Why Hormone Optimization Matters For Mood, Sleep, Libido, and Metabolic Health

When patients tell me, “I feel on edge,” “I keep waking between 2 and 4 AM,” or “my drive is gone,” I recognize a classic neuroendocrine pattern. Diminished hypothalamic-pituitary-gonadal (HPG) axis signaling reduces testosterone and estradiol output, while perimenopausal progesterone decline weakens GABAergic calm. These shifts reverberate across serotonin, dopamine, and GABA networks, raising anxiety, fragmenting sleep, and flattening motivation. Inflammation and autonomic imbalance amplify the effect, often creating chronic pain and metabolic headwinds.

What this means physiologically:

  • HPG axis downshift: Aging and stress blunt luteinizing hormone (LH) pulsatility, lowering gonadal output (Rosen et al., 2024).
  • Neurotransmitter modulation: Lower sex steroids weaken dopaminergic and GABAergic tone, elevating anxiety and impairing sleep maintenance (Akhter et al., 2023).
  • Progesterone and GABA-A: Loss of progesterone’s neurosteroid effect reduces slow-wave sleep and emotional regulation (Freeman et al., 2022).
  • Pain and autonomic nervous system: Hormonal insufficiency increases central sensitization and sympathetic overdrive, compounding insomnia and fatigue.

In my practice, normalizing bioavailable testosterone in men and restoring estradiol-progesterone balance in women, coupled with circadian alignment and autonomic-focused care, often resolves those 2–4 AM awakenings and stabilizes mood and energy.

My Stepwise, First-Person Roadmap: Layering Therapies With Precision

I have learned that throwing everything at once—testosterone, estradiol, progesterone, thyroid support, DHEA, supplements—creates diagnostic fog. Instead, I use a layered strategy that respects pharmacokinetics and endocrine feedback loops:

  • Start with the most likely driver based on symptoms and labs.
  • Add one or two interventions at a time.
  • Reassess at time points aligned with the modality’s kinetics (for example, 2–4 weeks for gels/patches; 4–5 weeks for pellets).
  • Adjust carefully using validated symptom scales (e.g., the Menopause Rating Scale), targeted labs, and patient-reported outcomes.

This approach lets me see what truly works, minimize side effects, and personalize therapy to receptor sensitivity and time since menopause.

References: Menopause Rating Scale (Heinemann et al., 2004)

Testosterone: Why It Matters For Men And Women

Testosterone is not just about muscle; it is a neuro-metabolic hormone:

  • Motivation and hedonic drive: Supports dopaminergic tone and reward pathways; loss contributes to anhedonia.
  • Vascular and erectile health: Via nitric oxide synthase, supports nocturnal erections; loss predicts erectile dysfunction.
  • Metabolic benefits: Improves lean mass and insulin sensitivity, reducing metabolic resistance (Morgentaler et al., 2022).
  • Analgesic modulation: Calms central sensitization through GABAergic and opioidergic systems.

For women, physiologic low-dose testosterone can restore libido, energy, and cognitive clarity. However, women are more sensitive to peaks and cumulative exposure. I manage dose and route meticulously to minimize voice changes, androgenic alopecia, and hirsutism while prioritizing symptom relief over chasing arbitrary numbers. The most clinically meaningful lab in women is often direct free testosterone, not calculated free testosterone (Rosner et al., 2007).

References:

Estradiol and Progesterone: Thermoregulation, Sleep, and Endometrial Safety

Estradiol supports thermoregulatory stability, serotonergic tone, and vascular health. Progesterone enhances GABA-A signaling and slow-wave sleep while protecting the endometrium when systemic estrogen is prescribed.

  • In postmenopausal women, transdermal estradiol reduces vasomotor symptoms and improves lipids and insulin sensitivity with lower thrombotic risk than oral routes (Stuenkel et al., 2023; The North American Menopause Society, 2023).
  • Women with a uterus who take systemic estradiol need micronized oral progesterone, typically 200 mg nightly for endometrial protection (NAMS, 2023). Progesterone creams are not sufficient for this purpose.
  • In perimenopause, estradiol fluctuations are the rule. I start low and focus on smoothing swings rather than mimicking postmenopausal dosing, then add progesterone for sleep and mood stabilization.

References:

Choosing The Right Route: Pellets, Injections, Patches, Gels/Creams, and Sublingual

Pellets: Continuous, Steady-State Delivery

I favor pellets in many cases for their steady pharmacokinetics and convenience. Patients appreciate fewer peaks and troughs—often translating to steadier mood, sleep, and libido.

  • What I tell patients: Pellets are not practically reversible, so dosing must be thoughtful. Manufacturing quality matters; sustained-release subcutaneous designs reduce spikes and downstream side effects.
  • Women’s nuance: With pellets, even low doses may produce longer-lived androgenic effects in sensitive women. I set expectations and prefer conservative first insertions with close follow-up.

Clinical pattern I see: When transitioning from other pellets or injections to high-quality sustained-release pellets, the onset may feel slower, but stability improves, and mood volatility decreases.

Injections: Predictable for Men, Risky Peaks if Undersmoothed

For men, testosterone cypionate or enanthate injections are a mainstay. Typical starting points cluster near 200 mg IM weekly for a symptomatic 50-year-old, but I tailor by age, comorbidities, and free testosterone targets.

  • Peak management: Injections produce an early peak (24–72 hours), which can trigger aromatization and estradiol spikes, leading to mood swings or gynecomastia. I often split doses or transition to daily micro-dosing when sensitivity is high.
  • Monitoring: I track hematocrit, estradiol, lipids, and PSA per guidelines (Mulhall et al., 2022).

References:

Patches and Transdermal Creams/Gels: Absorption and Site Matters

Estradiol patches are reliable, insurance-friendly, and avoid first-pass metabolism. I titrate based on symptom severity, time since menopause, and receptor sensitivity (NAMS, 2023). For testosterone gels/creams, absorption varies by site: thinner, warmer, more vascular skin (e.g., scrotal/labial) tends to absorb better but may also carry a higher risk of local androgenic effects, such as follicular hair growth.

  • Lab timing caveat: Transdermal application can artifactually elevate serum levels if labs are drawn too soon after dosing. I standardize draw timing and prioritize clinical response (Stute et al., 2022).

References:

Sublingual/Rapid-Dissolve Tablets (RDT)

For women, RDT testosterone can be extraordinarily beneficial for libido and energy, commonly at 2 mg once or twice daily in my clinic. This route avoids first-pass metabolism and produces rapid shifts in symptoms, allowing flexible titration. For men, daily RDT requirements are often too high to be practical.

Clomiphene and Fertility-Preserving Strategies in Men

Clomiphene citrate increases endogenous testosterone by relieving hypothalamic-pituitary negative feedback, thereby boosting LH/FSH (Snyder et al., 2023). I consider clomiphene in younger men who want fertility preservation or who demonstrate secondary hypogonadism with robust gonadotropin responsiveness.

  • Age effect: As men enter their 40s–50s, LH pulsatility weakens, and clomiphene’s effect wanes. In these cases, direct testosterone replacement often becomes more reliable.

Reference:

Perimenopause, Menopause, and FSH: Dosing Strategy In Context

A pivotal question I ask every time is: Are cycles still occurring? Until 12 months without menses, I treat it as perimenopausal, where estradiol and FSH can fluctuate widely. In this phase, I start conservatively to smooth estrogen swings rather than pushing high doses, reducing the risks of mastalgia or breakthrough bleeding.

Postmenopause, I often titrate estradiol slowly and observe FSH as a long-view marker of sufficiency. While I do not “treat to a number,” seeing elevated FSH levels soften over months can mirror symptomatic improvements and gains in tissue health. I re-evaluate early on every 4–8 weeks, then space visits as stability increases.

References:

SHBG, Free Hormone, and Why Symptoms Lead

Sex hormone–binding globulin (SHBG) profoundly shapes free testosterone and estradiol. High SHBG can blunt clinical effects; low SHBG can magnify them. I measure SHBG and adjust doses accordingly, always led by symptoms and safety labs rather than rigid numerical targets.

For women in particular, I focus on direct free testosterone to capture bioavailable androgen status and avoid being misled by calculated free values that vary by lab method (Rosner et al., 2007). If symptoms persist despite high doses, I pause dose escalations and assess thyroid function, iron status, sleep quality, inflammation, and autonomic stress.

Integrative Chiropractic Care: Enhancing Autonomic Balance and Endocrine Resilience

Hormone signaling is not isolated chemistry; it is a system-wide conversation. Integrative chiropractic care helps regulate the autonomic nervous system, reduce myofascial pain, and lower inflammatory tone—potentiating endocrine therapies.

What I do in practice:

  • Autonomic balancing: Gentle spinal and rib mobilization, cervical-thoracic adjustments, and breathing retraining improve vagal tone and stabilize cortisol rhythms. Patients often report fewer 2–4 AM awakenings when sympathetic overdrive calms.
  • Myofascial release and mobility: Reduces nociception and central sensitization, which I find synergizes with hormone therapy’s analgesic effects.
  • Movement prescriptions: Progressive resistance training raises IGF-1, improves insulin sensitivity, reduces visceral adiposity, and can lower aromatase activity—benefiting both testosterone and estradiol dynamics.
  • Lifestyle coaching: Circadian light exposure, sleep regularity, protein timing, and HRV-guided stress practices support endocrine stability.

Clinical observations from my practice at ChiroMed:

  • Patients with chronic cervicothoracic tension often report early-morning awakenings; after six weeks of targeted mobilization and respiratory retraining, sleep continuity improves.
  • Men who react poorly to injection peaks tolerate therapy better when we implement daily micro-dosing and autonomic-focused care.
  • Women who struggled with creams frequently thrive on estradiol patches plus oral micronized progesterone, with low-dose RDT testosterone layered for libido and energy.

Supportive references:

Practical Protocols: Matching Route to Patient Needs

For Men

  • Start near 200 mg IM testosterone cypionate weekly, then adjust by 50–100 mg based on free testosterone, symptoms, hematocrit, and estradiol balance.
  • If sensitive to peaks, consider split injections or daily micro-dosing.
  • If fertility preservation matters, consider clomiphene with LH/FSH/testosterone and semen monitoring.
  • Integrate autonomic-balancing chiropractic care to stabilize sleep, mood, and adherence.

For Women

  • For systemic symptoms, start with a transdermal estradiol patch and add micronized oral progesterone 200 mg nightly for endometrial protection.
  • For libido/energy, add low-dose testosterone via RDT (e.g., 2 mg once or twice daily) or consider conservative pellet dosing with careful follow-up.
  • In perimenopause, start low to smooth swings and titrate slowly; in postmenopause, increase gradually while tracking symptoms and FSH over months.

Monitoring framework:

  • Symptoms and function: mood, sleep continuity, libido, strength, body composition, and pain.
  • Labs: total and free testosterone, estradiol, SHBG, CBC (hematocrit), lipids, fasting insulin or HOMA-IR; PSA for men; and targeted progesterone monitoring.
  • Reassess at 6–8 weeks early in therapy, then every 3–6 months.

Side Effects and How I Mitigate Them

  • Hirsutism (women): Lower dose, change route (e.g., RDT instead of pellets), or split dosing to avoid peaks.
  • Acne or oily skin: Smooth peaks by dividing doses; evaluate estradiol balance and SHBG.
  • Erythrocytosis (men): Lower dose, switch to split dosing, optimize hydration; consider phlebotomy if hematocrit remains high.
  • Sedation or breast tenderness with progesterone: Switch to a sublingual formulation or adjust timing/splitting.
  • Mood volatility with injections: Prefer daily microdosing, pellets, or patches to reduce peak-to-trough swings.

Clinical pearl: Lowering total testosterone does not always alleviate androgenic side effects in sensitive women; route and peak smoothing often matter more than the absolute dose.

Special Topics: Menstrual Migraine, SSRIs, and Lab Timing

  • Menstrual migraine: A baseline of steady transdermal estradiol often blunts the premenstrual drop that triggers headaches by dampening CGRP and trigeminovascular activation. I combine this with magnesium, riboflavin, and sleep stabilization when needed.
  • SSRIs and libido/weight: When SSRIs were started for hormonally driven mood shifts, I consider a careful taper once hormone therapy stabilizes mood and sleep—always with documented consent, clear written instructions, and coordination with mental health providers to avoid discontinuation syndrome.
  • Lab timing: I time labs by modality—4–5 weeks after pellet placement, 2–4 weeks after patches/gels, and use standardized timing after transdermal application to avoid artifacts.

References:

Foundational Corrections: Thyroid, Iron, Vitamin D, Inflammation, and Sleep

Hormone therapy works best on a solid physiologic foundation. I routinely evaluate and correct:

  • Thyroid function (TSH, free T4/T3) to support mitochondrial efficiency and receptor responsiveness.
  • Iron status (ferritin, iron panels) to optimize oxygen delivery and thyroid conversion.
  • Vitamin D for immune and endocrine modulation.
  • Inflammation (hs-CRP) and gut health to reduce cytokine interference and aromatase upregulation.
  • Sleep architecture and circadian timing to normalize cortisol, leptin, ghrelin, and insulin dynamics.

Correcting these domains often shortens time-to-response and improves durability of outcomes.

Clinical Vignettes From My Practice

  • A 48-year-old perimenopausal woman with severe night sweats and 2–4 AM awakenings did not respond to creams. We transitioned to an estradiol patch plus oral micronized progesterone, and layered 2 mg RDT testosterone for libido. We combined cervical-thoracic mobilization and breathing retraining. By her second follow-up, awakenings diminished, libido improved, and she reported calmer days.
  • A 55-year-old man on high-dose weekly injections experienced mood swings and gynecomastia. We split his dose, added morning light exposure and HRV-guided breathwork, and addressed thoracic stiffness. Symptoms eased, energy stabilized, and labs normalized.
  • A 62-year-old woman, 12 years postmenopause, had high FSH and profound vasomotor symptoms. We titrated estradiol slowly (transdermal), added micronized progesterone, and monitored FSH over months as symptoms improved. Gentle resistance training and vitamin D optimization enhanced metabolic benefits.

Safety, Shared Decision-Making, and Documentation

  • I use micronized oral progesterone for endometrial protection when systemic estradiol is prescribed in women with a uterus.
  • I avoid non-standard compounded routes without a clear rationale and documented informed consent.
  • I align breast screening and PSA monitoring with guidelines and shared decisions.
  • I standardize follow-up intervals, written instructions (e.g., for SSRI tapering), and consent documentation—not as bureaucracy, but as patient safety.

Putting It All Together: A Modern, Integrative Pathway

  • Respect physiology with layered dosing and timing that matches pharmacokinetics.
  • Choose routes that fit the patient’s biology and goals: pellets for convenience and stability; patches/gels for fine control; RDT for flexible day-to-day management; and injections with peak smoothing where appropriate.
  • Prioritize symptoms and function over chasing numbers; use labs to ensure safety, guide trends, and calibrate dose.
  • Integrate chiropractic care to balance autonomics, resolve pain generators, and reduce inflammation—because a calmer nervous system enhances endocrine resilience.
  • Build the foundation—thyroid, iron, vitamin D, sleep, nutrition, and movement—so hormones can do their best work.

When we honor receptor sensitivity, smooth pharmacokinetics, and the neuro-musculoskeletal context, patients often rediscover clarity, energy, libido, and truly restorative sleep. To me, that is the essence of modern, evidence-based, integrative hormone care.

References

Hormone Health, Metabolism, and Prostate Wellness

Hormone Health, Metabolism, and Prostate Wellness

Hormone Health, Metabolism, and Prostate Wellness

Abstract

In this educational post, I take you through a practical, clinician-tested roadmap to understanding and treating hormone-related metabolic dysfunctions across the lifespan—particularly the interplay among sex hormone–binding globulin (SHBG), insulin resistance, polycystic ovary syndrome (PCOS), DHEA dynamics, and prostate-specific antigen (PSA) decision-making for men’s health. Drawing on current research and my clinical observations at Chiromed and in integrative practice, I explain why SHBG is not your enemy, how gut-driven insulin resistance amplifies androgen effects, how to identify PCOS phenotypes that do not look “typical,” and how to merge modern therapeutics (GLP-1s, metformin, spironolactone) with lifestyle, nutrition, and integrative chiropractic care to restore function. I also walk through PSA interpretation using percent free PSA and velocity, and when to order a 3T multiparametric prostate MRI. You will find physiologic context, step-by-step reasoning, and practical protocols you can apply immediately.

Key topics that follow

  • SHBG physiology, clinical meaning, and why chasing a lower SHBG is usually counterproductive
  • Insulin resistance, the gut–ovary axis, and PCOS phenotypes and treatment logic
  • Practical dosing pearls for metformin, GLP-1 receptor agonists, and spironolactone
  • DHEA physiology, neurological roles, and targeted use in men and women
  • PSA, percent free PSA, velocity, and the role of 3T multiparametric MRI
  • Where integrative chiropractic, movement therapy, and neuromusculoskeletal care fit into endocrine-metabolic care plans

Understanding SHBG, Free Testosterone, and Metabolic Health

I often meet patients who are symptomatic for low testosterone despite “normal” total testosterone. The missing piece is frequently sex hormone–binding globulin (SHBG)—a carrier protein synthesized in the liver that binds androgens (with a higher affinity for testosterone than for estradiol) and regulates the amount of hormone that is free and bioavailable to occupy intracellular receptors.

Core physiology, clearly explained

  • SHBG binds circulating androgens. Bound hormone is transport-ready but not freely available to cross the cell membrane and activate intracellular androgen receptors.
  • The fraction that remains free (or loosely albumin-bound) is bioavailable and exerts physiologic effects in target tissues (muscle, brain, bone, skin, reproductive organs).
  • Hepatic SHBG synthesis is modulated by insulin, estrogen, and thyroid status. Hyperinsulinemia suppresses SHBG; estrogen and thyroid hormone tend to raise it.
  • Clinically, a low SHBG often signals insulin resistance, while a higher SHBG is frequently associated with favorable metabolic profiles.

Why this matters clinically

  • Patients with low SHBG often present with features of metabolic syndrome—even when A1c still looks “fine.” Multiple cohorts show that low SHBG is a predictive marker for insulin resistance, dysglycemia, and cardiometabolic risk in both women and men (Ding et al., 2009; Selva et al., 2007).
  • Chasing a lower SHBG to “free up” testosterone usually misses the root cause and may worsen risk. Raising insulin (e.g., by overeating refined carbohydrates) can drop SHBG, but at a clear metabolic cost.

Evidence snapshot

  • Prospective data indicate that low SHBG predicts incident type 2 diabetes in women and men independent of BMI and baseline glucose (Ding et al., 2009).
  • Mechanistically, hepatic insulin signaling downregulates SHBG gene expression (Selva et al., 2007), providing a direct pathway from insulin resistance to low SHBG.

Treatment logic you can trust

  • Goal: Improve insulin sensitivity and the liver’s metabolic set point rather than artificially forcing SHBG down.
  • When symptomatic hypogonadism coexists with low SHBG, you may need to “saturate” androgen receptors by optimizing total testosterone so that the available free fraction reaches clinical effectiveness. The parallel, long-term fix is to address metabolic drivers that normalize SHBG.

Integrative chiropractic fit

  • In our practice, optimized movement patterns, resistance training, and autonomic balance through chiropractic care and neuromusculoskeletal rehabilitation improve insulin sensitivity, lower systemic inflammation, and support hepatic health—mechanisms that indirectly help normalize SHBG. I find that restoring spinal mechanics and reducing pain enables patients to engage in consistent physical activity, a cornerstone for improving insulin signaling (see my practice observations at Chiromed).

PCOS, Insulin Resistance, and the Gut–Ovary Axis

PCOS is one of the most common endocrine disorders in women of reproductive age. Yet, it is easy to miss because many patients lack the classic triad of obesity, acne, and hirsutism. I routinely see athletic women with irregular cycles, dysmenorrhea, or infertility—sometimes the only obvious clue—who nonetheless have the hormonal signature of PCOS.

Current diagnostic framework

  • Rotterdam criteria: Diagnose PCOS when at least 2 of 3 are present:
    • Oligo- or anovulation (e.g., irregular or skipped cycles)
    • Clinical/biochemical hyperandrogenism (e.g., hirsutism, acne, elevated free testosterone)
    • Polycystic ovarian morphology (PCOM) on ultrasound
  • Note: Not all patients have ovarian cysts, and total testosterone may be normal while free testosterone is elevated due to low SHBG.

Useful lab patterns

  • Elevated LH: FSH ratio (often >2:1) in some premenopausal patients.
  • Low or low-normal SHBG, elevated free testosterone; often high DHEA-S in adrenal-dominant phenotypes.
  • Early insulin abnormalities and low SHBG can precede changes in A1c.

Why insulin resistance drives PCOS

  • Hyperinsulinemia stimulates theca cells in the ovary to increase androgen production while simultaneously suppressing hepatic SHBG synthesis, thereby increasing free androgens (Escobar-Morreale, 2018).
  • Gut dysbiosis and endotoxemia (LPS exposure) promote low-grade inflammation and worsen insulin signaling, propagating ovarian dysfunction (Zhang et al., 2019).

Atypical PCOS phenotypes I see

  • Lean, athletic women with:
    • Severe dysmenorrhea or irregular cycles
    • Elevated LH: FSH
    • High free T with normal total T
    • High DHEA-S
    • Minimal or no hirsutism/acne

This pattern demands a gut–metabolic workup even when body composition appears healthy. I frequently include stool microbiome testing when symptoms suggest dysbiosis.

Evidence-Based Treatment Algorithms for PCOS

My approach integrates metabolic therapy, targeted pharmacology, nutrition, and neuromusculoskeletal care.

  1. Normalize insulin signaling
  • Metformin: Start low (e.g., 500 mg nightly) and titrate slowly to 1,500–2,000+ mg/day as tolerated to reduce hepatic gluconeogenesis and improve insulin sensitivity. GI side effects often attenuate with gradual titration and extended-release forms (Rena et al., 2017).
  • GLP-1 receptor agonists (e.g., semaglutide, exenatide): Improve glucose-dependent insulin secretion, delay gastric emptying, reduce appetite, and facilitate weight loss; randomized trials show improved metabolic and reproductive outcomes in PCOS (Kahal et al., 2021; Elkind-Hirsch et al., 2008).
  • Mechanistic payoff: Lower insulin raises SHBG and reduces androgenic “noise,” restoring ovulatory signaling.
  1. Manage androgenic symptoms while root-cause care takes hold
  • Spironolactone: An aldosterone antagonist with androgen receptor–blocking activity; effective for hirsutism, acne. Typical doses 50–100 mg/day; allow 6–12 months for maximal effect (Brown et al., 2009).
  • Combined oral contraceptives (COCs) with antiandrogenic progestins (e.g., drospirenone-containing formulations) can raise SHBG and reduce free T; useful for cycle control and symptom relief when pregnancy is not desired (Teede et al., 2018).
  • Caution: Symptom control does not correct the insulin–ovary axis; keep metabolic therapy central.
  1. Nutrition, gut health, and inflammation
  • Anti-inflammatory, Mediterranean-style diet with adequate protein, fiber, and omega-3 fatty acids improves insulin sensitivity and reduces ovarian androgen production (Barrea et al., 2019).
  • Intermittent fasting (time-restricted eating) may improve insulin sensitivity and weight in appropriately selected patients; ensure adequate caloric intake and avoid in those with disordered eating tendencies (Patterson & Sears, 2017).
  • Microbiome support: Address dysbiosis, SIBO, and intestinal permeability where indicated; diet, prebiotic fiber, and evidence-based probiotics can improve metabolic parameters.
  1. Movement and integrative chiropractic
  • Consistent resistance training and aerobic exercise improve GLUT4 translocation, mitochondrial function, and insulin sensitivity. In my clinic, we pair individualized spinal and joint care with corrective exercise to reduce pain-related movement avoidance and enhance adherence.
  • Autonomic balance matters: Many PCOS patients show sympathetic dominance; hands-on care and breathing-based neuromuscular retraining can reduce allostatic load and support ovulatory recovery.
  1. Fertility trajectory
  • Expect cycles and ovulation to normalize over months to years as insulin sensitivity improves. I have seen patients regain regular ovulation and conceive after systematic, sustained metabolic and gut care—even in those previously considered “lean and healthy.”

Clinical pearls and cautions

  • Start androgen therapy cautiously in PCOS or insulin-resistant women with low SHBG. Given the higher free fraction, standard doses can overshoot, increasing the risk of side effects. Start low and titrate slowly if testosterone therapy is clinically indicated for other reasons.
  • Obtain LH and androgen panels in premenopausal patients with menstrual complaints or infertility—even if phenotype is nonclassic.
  • Consider GI testing (e.g., stool analysis) when symptoms or history suggest dysbiosis, IBS, or food-triggered inflammation.

SHBG: What to Avoid and What to Embrace

Common misconception

  • “Lower SHBG to increase free T.” This treats the lab number, not the disease process.

What to avoid

  • Strategies that raise insulin (e.g., high refined carbohydrate load) just to lower SHBG.
  • Unnecessary suppression of SHBG may worsen cardiometabolic risk.

What to embrace

  • Improve insulin sensitivity through nutrition, exercise, sleep optimization, stress modulation, and gut care.
  • Use medications like metformin and GLP-1 receptor agonists to shift the metabolic field when lifestyle alone is insufficient.

In my practice, when we prioritize insulin sensitivity and inflammation control, SHBG trends upward into healthier ranges, free testosterone normalizes relative to total testosterone, and symptoms improve without chasing lab artifacts.

PSA, Percent Free PSA, and Prostate MRI: Smarter Men’s Health

PSA screening has evolved. A single total PSA value is an imperfect signal. Two tools improve decision-making:

  • Percent free PSA (%fPSA): The fraction of PSA not bound to serum proteins. Lower %fPSA indicates a higher likelihood of malignancy at a given total PSA.
  • PSA velocity: The year-over-year change in PSA. Faster rises suggest higher risk.

How I interpret PSA in practice

  • If total PSA is elevated (e.g., >4.0 ng/mL), I obtain percent free PSA. General rules supported by meta-analyses:
    • %fPSA <10% = higher probability of prostate cancer
    • %fPSA 10–20% = intermediate zone; consider prostatitis treatment if symptomatic and retest in ~3 months
    • %fPSA >20% = lower probability; continue surveillance
  • Consider PSA velocity: An increase >0.35–2.0 ng/mL/year—context-dependent—merits further evaluation even if the absolute PSA is “within range” (Vickers et al., 2011).
  • Many benign factors elevate total PSA—intercourse, cycling, digital stimulation, BPH, prostatitis—but they do not significantly affect %fPSA, which is why I lean on percent free PSA for triage.

Imaging that changes outcomes

  • If risk remains concerning (low %fPSA, rapid velocity, suspicious DRE, or persistent PSA elevation), I order a 3 Tesla multiparametric prostate MRI (mpMRI). This modality improves lesion detection and helps target biopsies, reducing unnecessary procedures (Ahmed et al., 2017).
  • Most patients prefer an MRI over immediate biopsy, and mpMRI adds diagnostic clarity, including detection of chronic or acute prostatitis—a common cause of PSA bumps that I diagnose frequently.

Practical pearls

  • Finasteride lowers total PSA by roughly ~50% but does not meaningfully change %fPSA—interpretation should be adjusted accordingly.
  • Counsel patients to avoid prostate stimulation (e.g., ejaculation, vigorous cycling) for 48–72 hours before PSA sampling to reduce noise in total PSA.
  • If PSA and %fPSA suggest low risk, recheck in 3 months rather than rushing to biopsy.

Testosterone therapy timing

  • When PSA and urologic evaluation are reassuring, testosterone therapy can proceed with routine monitoring. I coordinate closely with urology, recognizing that practice styles vary.

DHEA Physiology, Brain Receptors, and When to Treat

Dehydroepiandrosterone (DHEA) and its sulfated form, DHEA-S, are produced primarily by the adrenal cortex and function as both endocrine prohormones and neurosteroids, with receptors and actions in the brain. Levels peak in the 20s and decline steadily with age. In both sexes, suboptimal DHEA can present as low vitality, depressed mood, impaired stress tolerance, and reduced sexual function—even when testosterone looks “good.”

Why DHEA matters

  • Neurosteroid action: DHEA modulates GABAergic and glutamatergic tone, supporting mood, cognition, and arousal (Maninger et al., 2009).
  • Peripheral conversion: DHEA can be converted to androgens and estrogens via tissue-specific enzymes; in women, a portion is converted to DHT in peripheral tissues, contributing to libido and sexual response.
  • Immunometabolic effects: DHEA has anti-inflammatory properties and may influence endothelial function and bone metabolism.

Clinical patterns I see

  • Women with adequate total and free testosterone who remain symptomatic for low libido or anorgasmia sometimes have low DHEA-S in the double digits. Carefully titrated DHEA supplementation often improves sexual function and overall well-being.
  • In men and women with persistent fatigue and low mood despite thyroid/hormone optimization, DHEA can be the missing link.

Dosing logic

  • I typically optimize thyroid and sex hormones first; DHEA often rises when metabolic stress decreases.
  • If DHEA-S remains suboptimal:
    • Women: 5–10 mg/day compounded DHEA; reassess at ~6 weeks
    • Men: 20 mg/day compounded DHEA; reassess at ~6 weeks
    • Over-the-counter options vary in potency; when used, I start around 25 mg/day with close follow-up.
  • Monitor for androgenic side effects, especially in PCOS (who often already have high DHEA-S); avoid in hyperandrogenic phenotypes.

Evidence notes

  • Studies link low DHEA-S to reduced well-being, depression, and sexual dysfunction, with improvements seen in targeted supplementation cohorts (Arlt et al., 1999; Wierman et al., 2014). Age-associated decline is robust and correlates with multiple health outcomes.

Why Integrative Chiropractic Care Belongs in Endocrine-Metabolic Programs

The neuromusculoskeletal system interfaces with the endocrine and immune systems through shared inflammatory and autonomic pathways. Here is how integrative chiropractic care fits, based on observations from my clinic and the scientific literature:

Mechanistic bridges

  • Inflammation: Chronic pain amplifies IL-6 and TNF-α signaling, worsening insulin resistance. By reducing nociceptive drive and improving joint mechanics, manual therapies can lower inflammatory load and facilitate activity.
  • Autonomic balance: Spinal and rib mechanics influence sympathetic/parasympathetic tone. Improved thoracic mobility and diaphragmatic function promote vagal activity, which supports glycemic control and gut motility—both key to the gut–ovary axis.
  • Movement competency: Targeted strength and mobility programs enhance GLUT4 activity in skeletal muscle, thereby improving insulin sensitivity and supporting healthy SHBG levels.

In practice at Chiromed

  • We build individualized plans that synchronize:
    • Spinal and extremity joint care to enable pain-free training
    • Progressive resistance training emphasizing posterior chain and hip mechanics
    • Aerobic conditioning at sustainable intensities
    • Breathing retraining and sleep hygiene to normalize cortisol rhythms
  • This approach improves adherence to metabolic prescriptions, enabling the nutrition and pharmacology to “land” in real life.

Search-optimized section title Practical Protocols and Case-Style Reasoning

Putting it all together, here is how I apply the logic in daily care.

When SHBG is low, and symptoms suggest androgen deficiency

  • Evaluate metabolic health: fasting insulin, lipids, liver enzymes, hs-CRP, A1c.
  • Address insulin resistance first-line with nutrition, exercise, sleep, and stress management; consider metformin and/or GLP-1 RAs.
  • If symptoms persist, carefully optimize testosterone with awareness that low SHBG increases free fraction—start low, titrate to symptom relief and physiologic targets.

When PCOS is likely, but the phenotype is atypical

  • Order LH, FSH, total and free T, SHBG, DHEA-S, fasting insulin/glucose, and consider stool testing.
  • Begin metabolic therapy plus symptom-directed therapy (spironolactone or COCs if appropriate and pregnancy not desired).
  • Integrate resistance training and chiropractic-guided movement plans to accelerate insulin sensitivity and ovulatory recovery.

When initiating or adjusting DHEA

  • Confirm suboptimal DHEA-S and symptom alignment (low mood, libido, vitality).
  • Start low, reassess in 6–8 weeks, and monitor for androgenic side effects.
  • Avoid in hyperandrogenic PCOS unless clearly indicated and monitored.

When PSA is elevated or changing fast

  • Obtain percent free PSA and calculate velocity.
  • If %fPSA <10% or velocity is concerning, proceed to 3T mpMRI; if prostatitis is suspected, treat and retest.
  • Collaborate with urology based on mpMRI and clinical findings; delay testosterone changes until evaluation clarifies risk.

Why We Use Each Technique: The Physiology Behind the Protocols

  • Metformin: Reduces hepatic gluconeogenesis and improves peripheral insulin sensitivity via AMPK activation; lowers insulin, allowing SHBG to normalize and free T to calm down.
  • GLP-1 receptor agonists: Enhance glucose-dependent insulin secretion, reduce appetite, and reduce systemic inflammation; improved ovulatory function reported in PCOS.
  • Spironolactone: Direct androgen receptor blockade plus inhibition of 5α-reductase at higher doses; symptom relief while metabolic causes are corrected.
  • DHEA: Restores neurosteroid tone and supports sexual function with selective peripheral conversion; used when clinically and biochemically indicated.
  • Integrative chiropractic and movement: Improves neuromechanics and reduces pain, enabling training volume and intensity that improve insulin sensitivity; enhances autonomic balance affecting gut and endocrine axes.

Final Takeaways for Patients and Providers

  • Think metabolically first: Low SHBG is often a metabolic distress signal, not a target to suppress.
  • PCOS can be lean and subtle: Free T, LH: FSH, and DHEA-S mapping, plus gut assessment, can catch atypical cases.
  • Combine symptom control and root-cause therapy: Use spironolactone or COCs for hirsutism/acne while you restore insulin sensitivity and gut health.
  • Use smarter PSA strategies: Percent free PSA and PSA velocity reduce unnecessary biopsies and guide timely imaging with 3T mpMRI.
  • Integrate care: When manual therapy, structured exercise, and metabolic medicine are aligned, recovery timelines shorten and outcomes improve.

References

Ahmed, H. U., El-Shater Bosaily, A., Brown, L. C., Gabe, R., Kaplan, R., Parmar, M. K., … Emberton, M. (2017). Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. The Lancet, 389(10071), 815–822.

Arlt, W., Callies, F., van Vlijmen, J. C. M., Koehler, I., Reincke, M., Bidlingmaier, M., … Allolio, B. (1999). Dehydroepiandrosterone replacement in women with adrenal insufficiency. New England Journal of Medicine, 341(14), 1013–1020.

Barrea, L., Marzullo, P., Muscogiuri, G., Di Somma, C., De Alteriis, G., Colao, A., & Savastano, S. (2019). Nutritional aspects of PCOS: an update. Advances in Nutrition, 10(2), 270–292.

Brown, J., Farquhar, C., Lee, O., Toomath, R., & Jepson, R. (2009). Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database of Systematic Reviews, (2), CD000194.

Ding, E. L., Song, Y., Manson, J. E., Hunter, D. J., Lee, C.-C., Rifai, N., … Liu, S. (2009). Sex hormone–binding globulin and risk of type 2 diabetes in women and men. JAMA, 301(17), 1777–1786.

Elkind-Hirsch, K., Marrioneaux, O., Bhushan, M., Vernor, D., & Bhushan, R. (2008). Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in obese polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism, 93(7), 2670–2678.

Escobar-Morreale, H. F. (2018). Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Human Reproduction Update, 24(6), 671–698.

Kahal, H., Aburima, A., Ungvari, T., Rigby, A. S., Coady, A. M., Vince, R. V., & Kilpatrick, E. S. (2021). The effect of GLP-1 receptor agonists on cardiovascular risk factors in women with PCOS. Endocrine, 71, 199–206.

Maninger, N., Wolkowitz, O. M., Reus, V. I., Epel, E. S., & Mellon, S. H. (2009). Neurobiological and neuropsychiatric effects of DHEA and DHEA-S. Psychoneuroendocrinology, 34(3), 273–286.

Patterson, R. E., & Sears, D. D. (2017). Metabolic effects of intermittent fasting. Annual Review of Nutrition, 37, 371–393.

Rena, G., Hardie, D. G., & Pearson, E. R. (2017). The mechanisms of action of metformin. Nature Reviews Molecular Cell Biology, 19(1), 31–44.

Selva, D. M., Hogeveen, K. N., Innis, S. M., & Hammond, G. L. (2007). Monosaccharide-induced lipogenesis regulates the human hepatic sex hormone–binding globulin gene. Journal of Clinical Investigation, 117(12), 3979–3987.

Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., … International PCOS Network. (2018). Recommendations from the international evidence-based guideline for the assessment and management of PCOS. Human Reproduction, 33(9), 1602–1618.

Vickers, A. J., Savage, C., O’Brien, M. F., Lilja, H. (2011). Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. Journal of Clinical Oncology, 29(33), 447–453.

Gut Health and Hormone Balance Treatment

Gut Health and Hormone Balance Treatment

Gut Health and Hormone Balance Treatment

Abstract

I am Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In this educational post, I guide you through the science and practice of optimizing hormones by treating the gut–liver–hormone axis and reinforcing micronutrient and mitochondrial foundations. I explain how dysbiosis, intestinal permeability, and microbial enzymes like beta-glucuronidase reshape estrogen metabolism and influence conditions such as PCOS, endometriosis, and autoimmunity, and how lipopolysaccharide (LPS) and short-chain fatty acids (SCFAs) affect insulin sensitivity, mood, and inflammation. I translate current research on vitamin D, K2, iodine, selenium, methylated B vitamins, DIM, and shilajit into clinic-ready protocols, and I show where integrative chiropractic care fits by supporting vagal tone, motility, neuromusculoskeletal dynamics, and autonomic balance. You will find practical frameworks, dosing concepts, lab-monitoring advice, and rationale for each intervention, with citations to leading researchers.

Why Hormones Are Microbiome-Dependent: The Gut–Liver–Hormone Axis

When I first connected hormone symptoms to gut physiology, I saw a pattern: many “hormone” problems began as microbiome and barrier problems. The gut microbiome—a complex community of bacteria, viruses, fungi, and archaea—regulates digestion, immune tolerance, barrier integrity, and the enterohepatic circulation that clears estrogens. From the earliest studies linking metabolic endotoxemia to insulin resistance, it has become clear that LPS-driven inflammation can disrupt cardiometabolic and reproductive health (Cani et al., 2007).

  • When the microbiome is balanced, commensals generate SCFAs (notably butyrate) that nourish colonocytes, tighten junctions, and reduce inflammatory signaling.
  • When dysbiosis develops, beta-glucuronidase-producing taxa expand, and LPS permeates, amplifying NF-κB cytokine cascades that alter hormone receptors, hepatic detoxification, and insulin signaling (Fasano, 2012; Slyepchenko et al., 2017).

Clinically, if you manage estrogen symptoms, insulin resistance, or autoimmune patterns, you are managing the microbiome—whether you realize it or not.

Dysbiosis and Leaky Gut Explained: Distinct Problems that Reinforce Each Other

Two related but distinct issues commonly coexist:

  • Dysbiosis: A shift away from beneficial microbes, with loss of diversity and expansion of pathobionts. Consequences include increased LPS, altered bile acid signaling, and elevated beta-glucuronidase.
  • Leaky gut (increased intestinal permeability): Disruption of tight junction proteins (occludin, claudins, ZO-1) allows antigens and endotoxins to enter circulation, thereby increasing systemic inflammation and immune activation (Fasano, 2012).

Why that matters for hormones:

  • LPS activates TLR4–NF-κB, increasing TNF-α, IL-1β, and IL-6—cytokines that reduce insulin signaling and alter steroid hormone receptor function (Cani et al., 2007).
  • Permeability increases immune load and oxidative stress, thereby consuming methyl donors and glutathione needed for safe phase II detox (methylation, glucuronidation, sulfation) of estrogens.

I screen for these drivers whenever patients report PMS, heavy cycles, PCOS features, endometriosis pain, acne or hair loss, mood changes, fatigue, or autoimmune flares. Correcting the gut often increases the safety and efficacy of hormone therapy.

Estrogen Metabolism 101: Enterohepatic Circulation and the Estrobolome

The liver metabolizes estrogens via phase I hydroxylation (CYP1A1, CYP1B1) and phase II conjugation (COMT methylation, glucuronidation, sulfation). Conjugated metabolites pass into bile and should be excreted. In dysbiosis, microbial beta-glucuronidase deconjugates these estrogens, promoting reabsorption and recirculation—the biochemical basis of “estrogen dominance,” even with careful dosing (Plottel & Blaser, 2011).

  • 2-hydroxylation generally produces less proliferative metabolites.
  • 4- and 16α-hydroxylation yield more proliferative or potentially genotoxic metabolites if methylation and conjugation are suboptimal.

In complex cases or when there is a family history of estrogen-dependent cancers, I consider urinary metabolite testing to map pathways and guide targeted support.

PCOS, Endometriosis, and Autoimmunity: What the Microbiome Adds

Recent studies sharpen the microbiome’s role:

  • PCOS: Dysbiosis with fewer SCFA producers and higher LPS correlates with insulin resistance, hyperandrogenism, and impaired GLP-1 signaling (Lindheim et al., 2017; Qi et al., 2019). Restoring butyrate producers improves metabolic tone.
  • Endometriosis: Altered microbiota, increased permeability, and immune activation correlate with symptom severity. Increased beta-glucuronidase raises estrogen recirculation that can exacerbate lesions and pain (Chen et al., 2017; Jiang et al., 2017).
  • Autoimmunity: Barrier dysfunction and loss of tolerogenic species permit pathobiont translocation and molecular mimicry, priming autoimmune activity (Manfredo Vieira et al., 2018).

Clinical translation: Addressing the gut can reduce hormone dosing requirements, expand the therapeutic window, and stabilize mood, sleep, and metabolism.

The Simple Question with Big Impact: Are You Pooping Daily?

I ask every patient: “Do you have a daily bowel movement?”

  • Estrogen metabolites exit via bile and stool. Constipation increases residence time, giving beta-glucuronidase more opportunity to deconjugate and recirculate estrogens.
  • Correcting bowel habits is a core risk-reduction strategy for estrogen-driven conditions.

Practical steps I use:

  • Increase hydration and electrolytes.
  • Ramp fiber to 25–35 g/day; add PHGG (partially hydrolyzed guar gum) 4–6 g/day for low-bloat prebiotic support.
  • Add magnesium glycinate or citrate at night for stool regularity and sleep.
  • Encourage postprandial walks and vagal toning (slow exhale breathing, humming).

A 3-by-3 Framework for Gut Repair: Remove, Replace, Repair

To keep things doable, I use a 3-by-3 approach:

  1. Remove/Reduce Irritants
  • Clean up the diet: favor whole foods; limit alcohol, ultra-processed items, added sugars; consider a gluten-light or gluten-free trial for sensitive individuals.
  • Medication review: minimize NSAIDs and PPI overuse when clinically safe.
  • Stress load: hard-wire breath work, walks, and sleep hygiene.
  1. Replace and Restore
  • Fiber and prebiotics: 25–35 g/day total fiber; add PHGG for gentle SCFA support.
  • Probiotics: multi-strain Lactobacillus and Bifidobacterium blends (e.g., L. rhamnosus GG, B. lactis) for barrier and immune balance.
  • Digestive support: bitters and meal hygiene for hypochlorhydria/slow motility; phosphatidylcholine and balanced fats for bile flow.
  1. Repair and Rebalance
  • Barrier repair: L-glutamine 5 g/day, zinc carnosine, N-acetyl-D-glucosamine, omega-3s as indicated.
  • Inflammation control: Berberine for dysbiosis-associated endotoxemia; curcumin and quercetin for NF-κB calming.
  • Lifestyle anchors: 150 minutes/week activity; 10-minute post-meal walks; consistent 7–9 hours of sleep.

Why this approach works:

  • Prebiotics increase SCFAs, reinforce tight junctions, and support T-regs via HDAC inhibition.
  • Probiotics competitively inhibit pathobionts, reduce beta-glucuronidase activity, and enhance mucosal IgA.
  • L-glutamine fuels enterocytes and accelerates barrier recovery.
  • Berberine improves the microbial balance and activates AMPK to improve insulin sensitivity.

Nutrient Foundations for Receptor-Level Hormone Action: D, K2, A, Magnesium, Iodine, Selenium, and Methylation

I frequently see patients with robust serum hormones but poor tissue effects. The missing link is often receptor signaling, cofactors, and membranes.

  • Vitamin D3 behaves like a secosteroid hormone that modulates transcription through the VDR. Low vitamin D is associated with all-cause and cardiovascular mortality and can blunt androgen signaling even when total testosterone appears normal (Pilz et al., 2011; Holick, 2017).
  • Magnesium is a cofactor for D activation (25- and 1α-hydroxylases); deficiency dampens VDR signaling (Rosanoff et al., 2016).
  • Vitamin K2 directs calcium into bone and away from soft tissues by activating matrix Gla protein and osteocalcin; it complements D to protect vessels and build bone (Schurgers & Vermeer, 2000; Beulens et al., 2013).
  • Vitamin A supports epithelial integrity, immune balance, and nuclear receptor synergy with vitamin D.

I often use an ADK formula (D3 with K2 and A) alongside magnesium to safely improve receptor-mediated effects, while monitoring 25(OH)D, calcium, and PTH (Rosen et al., 2012).

Thyroid resilience: iodine and selenium synergy

  • Iodine is essential for T4/T3 synthesis, but safe utilization depends on selenium-dependent enzymes (glutathione peroxidases, thioredoxin reductases) to quench the H2O2 generated during iodide organification (Ventura et al., 2017).
  • Inadequate selenium increases oxidative stress at the thyroid, raising the risk of autoimmunity when iodine intake rises (Gartner & Gasnier, 2003).
  • I pair iodine (200–400 mcg) with selenium (100–200 mcg selenomethionine) and often zinc (10–30 mg), titrated to labs and symptoms (Zimmermann & Boelaert, 2015).

Methylation for estrogen safety

  • Methylated B vitamins—methylfolate and methylcobalamin—support COMT-mediated methylation of catechol estrogens, reducing genotoxic stress and stabilizing phase II clearance.

These micronutrients are the bedrock that allows hormones to “dock” and trigger healthy cellular responses.

DIM and Estrogen Metabolites: Steering Toward Safer Pathways

Diindolylmethane (DIM) shifts estrogen metabolism toward 2-hydroxylation and away from 16α- and 4-hydroxylation pathways associated with proliferative and genotoxic risk (Zeligs et al., 2006; Reed et al., 2006). Preclinical studies suggest that DIM may also upregulate BRCA1 signaling and promote apoptosis in cancer cell lines (Fan et al., 2009; Li et al., 2010).

How I apply it:

  • Women with estrogen-dominant symptoms or unfavorable metabolite profiles: 150–300 mg/day, adjusted to labs and tolerance.
  • Men with prostate risk or aromatization-driven symptoms: 300–600 mg/day, personalized.
  • I pair DIM with omega-3s, iodine/selenium, and fiber/probiotics to support the entire estrobolome–liver–stool axis.

Rationale: By changing metabolite balance and supporting conjugation, DIM decreases receptor overstimulation and DNA-adduct risk while improving symptom stability.

Shilajit for Free Testosterone and Mitochondrial Support

Some patients—particularly young males—present with high total testosterone but low free testosterone and low vitality. Shilajit, a purified, fulvic-acid–rich resin, has randomized data showing increases in total (~31%), free (~51%), and DHT (~37%) over ~90 days at 250 mg twice daily (Pandit et al., 2016). Mechanisms likely include improved mitochondrial function, nutrient transport, and hypothalamic–pituitary–gonadal signaling.

How I use it:

  • In those seeking endogenous support without exogenous hormones, I combine shilajit with vitamin D, magnesium, zinc, B12, and iodine/selenium when indicated, then track changes in free T, SHBG, energy, and body composition.

Why this works: Enhancing mitochondrial ATP and cofactor availability raises tissue responsiveness; changes in binding dynamics can increase the bioactive fraction without pushing total testosterone to excessive levels.

Vitamin D as a Systemic Modulator: Barrier, Immunity, and Receptors

I routinely optimize vitamin D because it acts at the intersection of immunity, barrier integrity, and endocrine signaling. Observational data tie suboptimal 25(OH)D to higher risks across diseases (Bouillon et al., 2019). Mechanistically, D supports tight junction proteins, cathelicidin, and endocrine receptor sensitivity. Clinically, many patients feel “stuck” until D is restored to an optimal range; I often target 60–80 ng/mL with appropriate monitoring to avoid hypercalcemia (Holick, 2017; Rosen et al., 2012).

Integrative Chiropractic Care: The Neuroimmune–Endocrine Interface

As a chiropractor and nurse practitioner, I see daily how autonomic balance, fascial mobility, and pain modulation determine whether patients can absorb nutrients, move consistently, and sleep well—foundations for endocrine success.

  • Vagal tone and motility: Gentle spinal and cervical adjustments can influence autonomic balance, improving gut motility, secretory IgA, and anti-inflammatory vagal pathways. Patients with low vagal tone present with constipation, bloating, and poor stress resilience.
  • Fascia and diaphragm: Thoracolumbar fascial restrictions and diaphragmatic stiffness impair breathing mechanics and lymphatic flow, promoting sympathetic overdrive. Mobility restores circulation and reduces pain.
  • Pain reduction without NSAIDs: Lowering nociception decreases cortisol and protects the mucosa from NSAID-induced permeability.
  • Behavioral activation: When pain decreases, patients walk, train, and sleep—activities that increase SCFAs, improve insulin sensitivity, and stabilize mood.

These neurophysiologic effects align with published observations on autonomic modulation and musculoskeletal care (Pickar, 2002; Lehman et al., 2012) and help nutrition and endocrine strategies “stick” in daily life.

For examples of how we operationalize this, see my resources at Chiromed and my professional updates on LinkedIn.

A Phased, Clinic-Ready Protocol for Gut and Hormone Optimization

I layer care to build momentum and safety.

Phase 1: Stabilize and Build Trust (Weeks 0–4)

  • Ensure daily bowel movements; add PHGG, hydration, and magnesium as needed.
  • Start a multi-strain probiotic (Lactobacillus + Bifidobacterium).
  • Begin vitamin D3 with K2 and magnesium; consider ADK formulations.
  • Introduce walks after meals and fixed sleep schedules.
  • Provide chiropractic adjustments and diaphragmatic work to normalize autonomics and reduce pain.
  • Baseline labs: CBC, CMP, 25(OH)D, calcium, PTH, thyroid panel (TSH, free T4/T3), thyroid antibodies as needed, ferritin, B12, folate, magnesium, zinc, selenium, CRP, fasting insulin/glucose, lipid profile, estradiol, total and free testosterone, SHBG.

Phase 2: Targeted Gut Repair and Hormone Pathways (Weeks 4–12)

  • Add L-glutamine 5 g/day for barrier support when indicated.
  • Short berberine course for endotoxemia/dysbiosis; replete with probiotics.
  • Add DIM if clinical or metabolite data show proliferative pathways.
  • Start a methylated B complex to support COMT and phase II detox.
  • Maintain chiropractic care cadence for autonomic and biomechanical resilience.

Phase 3: Personalize, Monitor, and Maintain (Months 3+)

  • Reassess symptoms, bowel habits, and targeted labs; titrate to the lowest effective doses.
  • Reinforce lifestyle anchors: fiber intake, movement, sleep, and stress practices.
  • Schedule periodic tune-ups for the spine, fascia, and breath mechanics to sustain vagal tone and support recovery.

This sequencing respects physiology and behavior: patients feel better first, then commit to more significant changes—resulting in better adherence and durable outcomes.

Special Focus: PCOS and Endometriosis

PCOS

  • Emphasize insulin sensitization through fiber, postprandial walks, resistance training, and, where appropriate, berberine.
  • Reduce LPS: probiotics, polyphenols, and barrier repair to lower endotoxemia.
  • Consider inositols for ovulatory support alongside gut therapy.
  • Monitor androgenic symptoms as gut protocols progress; improvements often track with better bile acid and SCFA signaling.

Endometriosis

  • Reduce beta-glucuronidase pressure via probiotics and fiber to limit estrogen recirculation.
  • Calm neuroimmune inflammation with omega-3s, curcumin, and sleep optimization.
  • Use gentle movement and manual therapy to address pelvic floor tension and diaphragm mobility; sympathetic downshift reduces pain tone.
  • Coordinate with gynecology; gut protocols augment, not replace, indicated care.

Case Reflection: High Total Testosterone, Low Vitality

I saw an 18–19-year-old male with low mood, low energy, weight gain, and “low-T” symptoms. His total testosterone was ~900 ng/dL—clearly not low. What we found: very low vitamin D, low B12, and signs of micronutrient insufficiency. I started a robust B-complex, ADK (D3 + K2 + A), iodine paired with selenium, and magnesium. At follow-up, his mother said, “He’s a totally different person.” Energy, mood, and cognition improved, and multiple medications were discontinued. The physiology: hormones were present, but receptor signaling and cellular machinery were underpowered. Restoring micronutrients enabled the hormones to “work.”

In other young men with high total but low free testosterone, I have added shilajit and structured resistance training. Free fractions improved, and vitality followed—without pushing total testosterone into excess.

Safety, Lab Monitoring, and Personalization

  • Monitor: 25(OH)D, calcium, PTH for vitamin D repletion; thyroid panel and antibodies for iodine–selenium strategies; ferritin, B12, folate, magnesium, zinc, selenium, CRP for micronutrient and inflammatory status; sex hormones including free testosterone and SHBG.
  • Adjust doses to labs and symptoms. If vitamin D stays low despite oral dosing, assess bile flow, fat absorption, and adherence; consider supervised loading.
  • Cautions:
    • Vitamin A: avoid hypervitaminosis; use caution in pregnancy.
    • Iodine: go slowly with autonomous nodules or hyperthyroidism; collaborate with endocrinology.
    • Zinc: long-term high dosing can lower copper; keep the balance.
    • DIM and shilajit: use third-party-tested products; personalize the dose.
    • Berberine: short targeted courses; watch for GI sensitivity and drug interactions.

How Integrative Chiropractic Care Complements Endocrine and Gut Strategies

Mechanistically, chiropractic-informed care bridges biochemistry and behavior:

  • Reduces nociception and sympathetic overdrive, lowering cortisol drag on thyroid conversion and gonadal axes (Lehman et al., 2012).
  • Improves respiratory mechanics and fascial glide, supporting lymphatic flow, nutrient delivery, and waste clearance.
  • Enhances vagal tone, supporting motility, secretory IgA, and peristalsis—foundations for microbiome stability.
  • Facilitates movement prescriptions (resistance training, mobility, aerobic intervals) that reduce aromatase activity, improve insulin sensitivity, and raise androgen receptor density.

In my practice, patients combining endocrine protocols with spinal–fascial optimization report better sleep, steadier energy, more predictable lab trajectories, and lower required doses—an elegant synergy of systems biology and hands-on care. Explore our integrative approach at Chiromed and my professional notes on LinkedIn.

Why Each Technique Matters: Systems Biology Rationale

  • Fiber/PHGG: Feeds SCFA producers, tightens junctions, and supports GLP-1 signaling.
  • Probiotics: Reduce beta-glucuronidase, improve barrier integrity, and temper endotoxemia.
  • L-glutamine: Primary fuel for enterocytes; accelerates epithelial repair.
  • Berberine: Reshapes the gut microbiota, lowers LPS levels, and activates AMPK to improve insulin sensitivity.
  • DIM: Steers estrogen toward 2-hydroxylation, lowering proliferative load.
  • Methylated B vitamins: Enable COMT activity and conjugation; reduce genotoxicity of catechol estrogens.
  • Vitamin D + K2 + A + Mg: Align receptor signaling and calcium kinetics; protect vessels and bone.
  • Iodine + selenium: Support thyroid synthesis while detoxifying H2O2 to prevent autoimmune escalation.
  • Shilajit: Enhances endogenous androgens via mitochondrial and HPG-axis support.
  • Chiropractic care: Normalizes autonomic function, reduces pain, and supports movement habits that sustain microbiome and endocrine gains.

Each intervention nudges a different lever; together, they realign the system.

Clinical Observations from Practice

Across patient cohorts at my clinic, we see reproducible patterns:

  • Resolving constipation reduces PMS and “estrogen rollercoaster” symptoms within weeks.
  • Regular adjustments correlate with improved sleep and stress tolerance, enabling consistent training and meal timing that benefit the microbiome.
  • Vitamin D optimization often coincides with improved mood, less joint pain, and better responses to both gut and hormone protocols.

These observations are consistent with the mechanistic and clinical literature, reinforcing the rationale for why foundational steps deliver outsized results. For more, visit Chiromed and my LinkedIn updates.

References

Hormone Balance, Iron Health, and Contraceptive Care

Hormone Balance, Iron Health, and Contraceptive Care

Hormone Balance, Iron Health, and Contraceptive Care

Abstract

As a clinician blending chiropractic, functional medicine, and advanced nursing practice, I see how hormone physiology, micronutrients, and systems biology converge to shape health, recovery, and resilience. In this educational post, I walk you through practical, evidence-informed strategies for evaluating iron deficiency and ferritin; interpreting cortisol and thyroid dynamics; selecting and titrating progesterone, estrogen, and testosterone in complex scenarios (PCOS, IUD selection, male fertility and TRT rebound, TIA and stroke risk considerations, endometriosis, and menopause); and understanding the nuanced oncology context around DCIS and hormone receptors. I also explain how integrative chiropractic care fits into these plans by balancing the nervous and hormone systems, improving body functions, and supporting health through hands-on therapy, exercise, sleep, and diet. Throughout, I present current literature from leading researchers and add real-world observations from my practice (DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST) to help you translate physiology into precise, patient-centered care.

Foundations Of Identity In Care Planning And Clinical Context

  • Why this matters: Many patients navigate multiple identities—athlete and parent, caregiver and executive, patient and advocate. Clinically, multiple identities often map onto competing physiological stresses: sleep compression, high allostatic load, and variable patterns of nutrition and movement. Recognizing these factors is the first step in aligning care with lived realities.
  • Integrative chiropractic fit: In my clinic, identity-informed care plans build adherence. When I address spine and fascial mechanics and autonomic balance with targeted manual therapy, patients experience immediate relief that reinforces engagement with longer-term hormonal and nutritional strategies. Clinically, I see better follow-through on lab timing, supplement dosing, and structured movement when the body feels aligned and capable.

Iron Physiology, Ferritin, And Root-Cause Mapping

Understanding iron requires separating storage, transport, and utilization:

  • Key biomarkers:
    • Serum ferritin: a proxy for iron stores but an acute-phase reactant—elevates with inflammation (hepcidin-mediated sequestration).
    • Serum iron and transferrin/TIBC: reflect circulating iron and binding capacity.
    • Transferrin saturation (%): often the most useful single index with ferritin.
    • Reticulocyte hemoglobin (CHr) and soluble transferrin receptor (sTfR): help distinguish true deficiency from anemia of inflammation.

Physiology in brief:

  • The liver peptide hepcidin governs iron absorption and release from macrophages. Inflammation increases hepcidin, lowering absorption and locking iron in stores—low iron availability with normal/high ferritin.
  • True iron deficiency presents with low ferritin, low iron, high TIBC, and low transferrin saturation. Anemia of chronic inflammation shows low iron, low/normal TIBC, and normal/high ferritin.

Why patients stay iron-deficient:

  • Decreased intake or high phytate/polyphenol diets limit absorption.
  • Malabsorption: hypochlorhydria, celiac spectrum, SIBO, gastric bypass.
  • Losses: heavy menses, GI blood loss, frequent phlebotomy, and endurance training.
  • Special populations: neonates can experience early postnatal physiologic shifts; in adults, postpartum, post-surgery, and endurance athletes require tailored screening.

Clinical approach I use:

  • Map the cause: hydration status, GI absorption, occult bleeding (including fecal immunochemical testing), menstrual history, PPI use, celiac panel if indicated, and inflammatory markers (CRP, ESR).
  • Replace iron physiologically: I favor alternate-day oral iron to align with hepcidin’s diurnal rhythm and reduce GI side effects, supported by recent randomized trials showing improved absorption with every-other-day dosing (Stoffel et al., 2017). Using ferrous bisglycinate or heme iron polypeptide can enhance tolerance.
  • Repletion targets: Bring ferritin to symptom-relief thresholds (often 50–100 ng/mL for fatigue and hair loss), then sustain. Monitor hemoglobin, ferritin, and transferrin saturation every 8–12 weeks during repletion.

Integrative chiropractic fit:

  • Manual therapies that improve thoracic mobility and diaphragmatic excursion enhance vagal tone and GI perfusion, supporting absorption. Coaching on timing iron away from calcium and with vitamin C-rich foods further increases uptake. I often see faster symptom improvement when we combine postural breathing retraining and gentle aerobic conditioning with iron repletion.

Hormonal IUDs, Progestin Families, And Thrombotic Risk

Not all progestins are the same. Families differ in androgenicity and thrombotic risk:

  • Levonorgestrel (Mirena and similar): primarily a local uterine effect with low systemic levels; robust evidence supports low VTE risk compared with systemic progestins (ACOG, 2022).
  • Norethindrone: different side-effect profile and hepatic metabolism from progesterone; systemic exposure carries VTE risk similar to combined oral contraceptives when used in combination with estrogen.
  • Biologic progesterone (micronized) differs from synthetic progestins in receptor activity and in metabolites (e.g., allopregnanolone), which influence mood and sedation.

Why are Levonorgestrel IUDs often well tolerated?

  • The local endometrial action results in reduced systemic exposure, decreased bleeding, and endometrial protection, with a favorable safety profile. This is one reason neurosurgical and periprocedural contexts prefer local or targeted effects when feasible—namely, to reduce systemic adverse events.

Integrative chiropractic fit:

  • Pelvic floor integration matters. I routinely coordinate pelvic floor assessment and diaphragmatic mechanics with IUD choice. Improved lumbopelvic control and reduced sympathetic arousal can decrease cramping and improve IUD tolerance.

Progesterone Strategy In Sensitive Patients And PCOS Contexts

Clinical problem: Some patients with PCOS or HPA dysregulation report mood lability with oral progesterone.

Physiology:

  • Oral micronized progesterone converts to allopregnanolone, a positive allosteric modulator of GABA-A receptors. In most, this is anxiolytic; in a sensitive minority, neurosteroid fluctuations can provoke dysphoria.
  • Sublingual and transdermal routes bypass some first-pass metabolism, altering metabolite profiles and CNS effects.

My approach:

  • Start with a low-dose oral micronized progesterone (e.g., 100 mg qHS) to promote sleep and provide endometrial protection. If not tolerated:
    • Switch to a sublingual troche at half the equivalent oral dose (sublingual tends to achieve higher bioavailability; clinically, 100 mg sublingual can approximate 200 mg oral).
    • Quartering a 200 mg troche yields ~50 mg sublingual aliquots for fine titration.
  • Why this works: By modulating route and dose, we can smooth neurosteroid peaks, reduce daytime sedation, and maintain endometrial safety when used with estrogen.
  • For PCOS on androgen therapy: Balance is critical. A small androgen signal can be synergistic for mood, energy, and libido, but carefully calibrate it with estrogen and progesterone to avoid endometrial hyperplasia, acne, or dyslipidemia. Track SHBG, lipids, and insulin resistance.

Integrative chiropractic fit:

  • Autonomic stabilization through cervical-thoracic manipulation and breathing retraining reduces adrenergic drive that often amplifies progesterone sensitivity. When we address sleep quality and nocturnal bruxism with TMJ and cervical work, I see smoother adaptation to progesterone in practice.

Cortisol Testing: Salivary Profiles Versus Serum

Why measure multiple points:

  • Cortisol follows a diurnal curve: a peak within 30–45 minutes after waking (CAR) and a gradual decline throughout the day. A single AM serum cortisol measurement may miss dysregulated patterns.
  • A 4–5-point salivary cortisol series captures CAR, midday, afternoon, and evening levels—useful for sleep disturbances, burnout, and suspected HPA axis alterations (O’Connor et al., 2021).

When I choose each:

  • For pattern analysis and sleep complaints: multi-point salivary cortisol.
  • For adrenal insufficiency screening or acute illness: AM serum cortisol ± ACTH stimulation.

Integrative chiropractic fit:

  • Chiropractic care and breath-led movement can normalize autonomic balance, often flattening hyper-adrenergic spikes that correlate with evening cortisol elevations. I pair care with light-in-the-morning, dim-in-the-evening routines to reinforce circadian rhythms.

Male Fertility, Clomiphene, And TRT Rebound

In men in their 20s–30s with low testosterone who want fertility:

  • I avoid long-term estrogen receptor blockade. Short courses of clomiphene citrate (3–6 months) can increase LH/FSH levels, thereby increasing endogenous testosterone and sperm counts (Helo et al., 2017). It is not for indefinite use due to visual and mood risks and potential lipid changes.
  • Off peptides/TRT: I use timed clomiphene or enclomiphene to accelerate spermatogenesis while lifestyle and nutrition restore HPG axis tone.
  • Foundational first: For younger men, I prioritize diet quality, sleep, resistance training, weight normalization, and correcting micronutrient levels (vitamin D, B-complex, zinc, magnesium). I frequently see total testosterone rise from low 300s into 700–800 ng/dL over 6–9 months with lifestyle adherence.

Integrative chiropractic fit:

  • Restoring thoracic mobility and rib mechanics improves breathing efficiency and training capacity; correcting lumbopelvic mechanics reduces systemic inflammation from overuse. The autonomic shift toward parasympathetic tone deepens sleep, which is crucial for nocturnal gonadal hormone secretion.

DCIS, Hormone Receptors, And Personalized Risk-Benefit

Terminology and nuance:

  • Ductal carcinoma in situ (DCIS) is a noninvasive neoplastic process confined to the ducts. While often called “stage 0 breast cancer,” it lacks stromal invasion; management varies widely.
  • Receptor positivity (ER, PR, AR) indicates ligand-responsive pathways. Receptors are normal cellular features; their presence does not inherently mandate systemic suppression in all contexts.

Standard-of-care realities:

  • Many oncology pathways default to anti-estrogen strategies (e.g., tamoxifen) in receptor-positive lesions. My stance: align with oncology for invasive disease or recent treatment, but individualize for remote history or post-mastectomy scenarios, considering symptom burden and quality-of-life outcomes (Early Breast Cancer Trialists’ Collaborative Group, 2011; Cuzick et al., 2011).

Clinical reasoning:

  • In a patient decades post-bilateral mastectomy with no residual breast tissue, the theoretical tissue-specific risk is different from that of a patient 6 months post-lumpectomy still on adjuvant therapy. I weigh the systemic benefits of estrogen (bone, vasomotor stability, cognition, urogenital health) against realistic tissue risks, use shared decision-making, and document this via informed consent.

Integrative chiropractic fit:

  • Many of these patients struggle with pain, sleep disruption, and deconditioning. Postural restoration, scar mobility work, and gentle strengthening reduce sympathetic load, allowing lower-dose hormone regimens to achieve symptom control.

TIA, Stroke Risk, And Sex Hormones

Historical concern has linked estrogen to stroke risk, particularly in oral forms and in older trials with higher doses started late after menopause. The modern view:

  • Route matters: Transdermal estradiol has a more favorable thrombotic profile than oral estradiol because it bypasses first-pass hepatic effects on clotting factors (Canonico et al., 2016).
  • Testosterone does not require routine discontinuation after TIA in carefully selected women and men; the focus is on global vascular risk management (blood pressure, glycemic load, sleep apnea, hematocrit monitoring in men on TRT).
  • In patients who received pellet therapy near a TIA event, I evaluate vascular risks comprehensively. Anecdotally and mechanistically, sustained androgen levels do not necessarily precipitate cerebrovascular events; confounding factors (dehydration, arrhythmia, migraine with aura, hypercoagulable states) must be assessed.

Why integrative care helps:

  • Cervical and upper thoracic biomechanical dysfunction can aggravate headaches and sympathetic tone. By improving cervical proprioception, rib mechanics, and breathing patterns, I observe reduced migraine frequency and better control of blood pressure variability, which complements hormone prudence.

Immediate-Release Versus Extended-Release In Symptom Relief

In my practice, I often choose immediate-release formulations when seeking neurosensory benefits (e.g., anxiolysis, sleep initiation) from agents with CNS effects because:

  • Faster onset can more directly target symptom windows (e.g., bedtime).
  • It allows finer titration and identification of dose-response relationships.

When I choose extended-release:

  • For hormones or agents where steady state is crucial to avoid peaks/valleys, or when side effects are dose-peak-related. Personalization is key.

Endometriosis And Menopause: Progesterone Essentials

Key principles:

  • In menopausal women with a history of endometriosis on estrogen therapy, I favor co-prescribing progesterone even without a uterus. Rationale: ectopic endometrial implants may persist extrauterine and remain hormonally responsive. Progesterone has anti-proliferative effects on endometrial tissue and may reduce the risk of malignant transformation (Vercellini et al., 2014).

Testosterone and endometriosis:

  • Testosterone generally has neutral direct effects on endometriotic lesions; symptom modulation is more indirect (energy, libido, mood). I monitor acne, hair growth, and lipids.

Integrative chiropractic fit:

  • Pelvic and lumbosacral mechanics impact pelvic congestion and pain. Coordinated pelvic floor therapy, sacroiliac mobilization, and graded movement often reduce pain and allow lower estrogen doses with better function.

Thyroid Physiology: T4, Reverse T3, And Desiccated Thyroid

Why do some patients struggle with isolated levothyroxine?

  • T4 to T3 conversion is context-dependent: inflammation (IL-6), chronic stress (cortisol), and caloric restriction increase deiodinase 3, generating reverse T3 as a protective brake.
  • Bolus T4 dosing can, in sensitive patients, drive higher reverse T3 and leave tissues relatively hypothyroid despite normal TSH and free T4.

When I consider combination therapy:

  • If free T3 is low-normal with symptoms and reverse T3 is elevated, a trial of T3 addition or desiccated thyroid can be considered, monitoring HR, BP, and symptoms.
  • Desiccated thyroid includes T1/T2 in addition to T4/T3; while evidence is mixed, some patients report improved well-being (Hoang et al., 2013). The physiologic appeal is a more native ratio of iodothyronines.

Dosing logic:

  • Keep total T3 exposure rational (avoid overtreatment). Many patients do well at conservative desiccated doses (e.g., 60–120 mg with split dosing) or modest liothyronine add-on.
  • If reverse T3 is persistently high, look upstream: inflammation, gut dysbiosis, iron deficiency, sleep apnea, and medications. Raising the dose alone rarely fixes a conversion problem.

Integrative chiropractic fit:

  • By improving sleep quality and decreasing pain, we reduce cortisol and catecholamine tone that can impair peripheral conversion. I frequently pair thyroid adjustments with gut-directed nutrition, iron repletion, and aerobic conditioning to normalize deiodinase activity.

Estriol, Estradiol, And Skin Or Urogenital Targets

  • Estriol (E3) is a weaker estrogen with higher affinity for ER-beta, associated with urothelial and skin benefits and a theoretical reduced proliferative risk profile (Labrie et al., 2017).
  • On its own, estriol is often too weak for vasomotor symptoms; patients may continue to have hot flashes with estriol pellets or low-dose creams.
  • Bi-est combinations (estriol + estradiol) can increase serum estradiol; monitor for bleeding. For vulvovaginal atrophy, low-dose local estradiol or estriol is typically effective with minimal systemic absorption.

Integrative chiropractic fit:

  • Postural improvement, hip mobility, and pelvic floor coordination augment local tissue perfusion and sexual function. Patients often need lower topical doses when musculoskeletal contributors are addressed.

TRT In Men: Hematocrit, Estradiol, And Practical Monitoring

For men on testosterone injections who feel great but develop high hematocrit:

  • Tactics include dose and interval adjustments, switching to transdermal forms, therapeutic phlebotomy if indicated, and addressing sleep apnea, hydration, and iron stores.
  • I monitor hematocrit, estradiol, SHBG, PSA, lipids, and blood pressure. Aromatization to estradiol can be beneficial for bone and mood; I avoid reflexive overuse of aromatase inhibitors and instead optimize dose and lifestyle.

Integrative chiropractic fit:

  • Correcting thoracic outlet and rib mechanics can support breathing and reduce sleep apnea severity alongside weight loss—a key driver of safer TRT hematology.

Gut-First When Thyroid Therapy “Should Work” But Doesn’t

When free T3 is approaching the target (e.g., 4.0+ pg/mL), yet patients still feel unwell:

  • I reassess gut health: dysbiosis, SIBO, post-viral inflammation, food sensitivities. The gut-liver axis modulates thyroid hormone metabolism and immune cross-talk, particularly in Hashimoto’s.
  • I commonly see symptom breakthroughs after:
    • Eliminating trigger foods (gluten in celiac spectrum; individualized otherwise),
    • Repleting selenium, zinc, iron, vitamin D, B12, and magnesium, and
    • Restoring sleep and movement rhythm.

Integrative chiropractic fit:

  • Vagal stimulation through breathing and thoracic mobilization, coupled with graded walking and core stability, improves motility and lowers systemic inflammatory tone.

Clinical Vignettes And Observations From Practice

  • Ferritin plateaus despite oral iron: With alternating-day dosing with vitamin C, stopping concurrent calcium, checking for H. pylori and celiac markers, and adding diaphragmatic breathing drills for reflux, patients often see ferritin rise to 60–100 ng/mL within 12–16 weeks. Combining manual therapy to reduce costal margin restriction improved tolerance of iron and reduced GERD complaints in my clinic.
  • Progesterone intolerance in perimenopause: Switching from 200 mg oral nightly to 50–100 mg sublingual in divided evening doses, plus cervical release and sleep hygiene, stabilized mood and sleep within two cycles for most sensitive patients.
  • Young male with low T and fatigue: A 9-month plan emphasizing whole-food nutrition, vitamin D repletion to 40–60 ng/mL, magnesium glycinate at night, and progressive resistance training raised total testosterone from 320 ng/dL to 760 ng/dL without medications. Thoracic mobility and hip hinge training improved recovery and adherence.
  • Post-DCIS symptom burden: In a patient more than a decade post-bilateral mastectomy with severe vasomotor symptoms, a carefully titrated transdermal estradiol patch with nightly progesterone, plus scapular mobility and postural rehabilitation, improved sleep and cognition. Shared decision-making and documented informed consent were essential.

Why Integrative Chiropractic Care Amplifies Endocrine Therapies

  • Autonomic regulation: Pain and joint dysfunction heighten sympathetic tone, disrupting sleep, glucose metabolism, and thyroid hormone conversion. Manual therapy, spinal mobilization, and breathing retraining shift HRV toward parasympathetic balance, creating a biological environment in which hormones function as intended.
  • Movement economy: Efficient biomechanics reduce inflammatory signaling from microtrauma and improve insulin sensitivity, crucial for PCOS, TRT safety, and thyroid action.
  • Adherence and feedback loops: Rapid musculoskeletal relief builds trust and momentum, making it easier to sustain nutrition, sleep, and medication regimens. Clinically, I consistently see greater lab improvements when patients are engaged in both structured movement and manual care.

Practical Protocol Checklists

Iron and ferritin

  • Assess ferritin, iron, TIBC, transferrin saturation, CRP, ESR, CBC, retic Hb.
  • Identify cause: menses, GI loss, malabsorption, diet, PPI use.
  • Replace with alternate-day dosing; recheck at 8–12 weeks.
  • Add diaphragmatic breathing and gentle conditioning.

Progesterone strategies

  • Start 100–200 mg oral micronized qHS; if intolerant, consider 50–100 mg sublingual divided.
  • For estrogen users, ensure endometrial protection.
  • In the history of endometriosis, there is a continued use of estrogen and progesterone even post-hysterectomy.

Cortisol evaluation

  • Use 4–5-point salivary cortisol to assess diurnal rhythm; AM serum for insufficiency screening.
  • Implement light therapy, sleep hygiene, and autonomic-balancing manual care.

Male fertility/TRT

  • For fertility: short-course clomiphene 3–6 months with lifestyle-based.
  • On TRT: monitor hematocrit, estradiol, SHBG, PSA, BP; address sleep apnea.
  • Optimize resistance training and recovery.

Thyroid optimization

  • If reverse T3 is high and symptoms persist, investigate inflammation and gut.
  • Consider T3 add-on or desiccated thyroid with careful monitoring.
  • Support with selenium, zinc, iron, and vitamin D; improve sleep and stress load.

Estriol/estradiol

  • Use local estradiol or estriol for urogenital symptoms; monitor if combining with estradiol systemically.
  • Expect estriol alone to be too weak for hot flashes.

Closing Perspective

Modern endocrine care thrives at the intersection of precise physiology and whole-person mechanics. When we calibrate hormones thoughtfully, correct nutrient deficits, and restore movement and autonomic balance, patients experience durable improvements in energy, cognition, metabolism, and quality of life. Integrative chiropractic care is not an add-on; it is a force multiplier—aligning the nervous system and musculoskeletal frame to receive and respond to biochemical therapies. My day-to-day observations mirror the literature: when we treat the individual and the system, outcomes follow.

References

A Modern, Integrative Approach to Thyroid Optimization

A Modern, Integrative Approach to Thyroid Optimization

A Modern, Integrative Approach to Thyroid Optimization

Abstract

For decades, the standard approach to treating hypothyroidism has centered on a single lab value—Thyroid-Stimulating Hormone (TSH)—and a single medication, synthetic T4 (levothyroxine). However, an increasing body of evidence and extensive clinical observations indicate that this approach is fundamentally flawed for a significant proportion of patients. Many individuals on T4-only therapy continue to suffer from debilitating hypothyroid symptoms like fatigue, weight gain, hair loss, and depression, despite their TSH levels appearing “normal.” This educational post will explore the intricate physiology of thyroid hormone, explaining why T4 is a prohormone and why active T3 is the key to metabolic health. We will deconstruct the limitations of TSH testing, explore the critical process of T4-to-T3 conversion, and introduce the problematic role of Reverse T3. Drawing from the latest evidence-based research and my own clinical experience, I will outline a more comprehensive, patient-centered approach to diagnosing and managing thyroid dysfunction. We will discuss the vital importance of Free T3 (FT3), the shortcomings of standard lab ranges, and the clinical benefits of combination therapy, including Natural Desiccated Thyroid (NDT). Furthermore, I will explain the critical, yet often overlooked, role of iodine and how integrative chiropractic care forms a foundational part of treatment by optimizing nervous system function and supporting the body’s innate ability to heal.

Rethinking Thyroid Care: Moving Beyond Outdated Protocols

As a practitioner with credentials spanning chiropractic, advanced practice nursing, and functional medicine (DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST), I have dedicated my career to challenging long-held conventions in healthcare to identify what truly works for patients. Today, I want to guide you on a journey into the world of the thyroid, and in doing so, I may need to unravel some of what you’ve come to understand from conventional medical training. My goal is not to create a new, complicated system but to return to a more fundamental, physiological truth. My goal is to assist individuals in returning to a lifestyle that aligns with the natural and optimal design of our bodies.

For over a decade, I’ve focused on this physiological approach, and the feedback from patients at my clinic has been overwhelmingly positive. They feel better, their symptoms resolve, and their lives are transformed. This isn’t based on a fad; it’s grounded in pure physiology. When we appreciate and work with the body’s intricate systems instead of against them, we see profound clinical success. This is particularly true when it comes to the thyroid.

Thyroid Hormone: Your Body’s Metabolic Engine

The thyroid hormone is the master regulator of your metabolism. It dictates the speed of nearly every cellular process in your body. Think of it as the engine’s pace car. It controls:

  • Energy Production: Your overall rate of energy expenditure.
  • Temperature Regulation: Why you might feel cold when others are comfortable.
  • Growth Rates: How fast your hair and nails grow.
  • Gastrointestinal Motility: The speed of your digestive system influences constipation or diarrhea.
  • Cellular Health: Research has even linked low levels of the active thyroid hormone T3 to an increased risk of certain cancers.

The Synthroid Paradox: Normal Labs, Persistent Symptoms

The most widely prescribed thyroid medication in history is levothyroxine, with Synthroid being the most recognizable brand name. Yet, in my clinical practice, I see a daily parade of patients who are taking it and are still miserable. I recently saw a patient who had been on a stable dose of Synthroid for years. Her endocrinologist told her that her labs were perfect, with a TSH of 1.5. Yet, her chart told a different story.

  • Chief Complaint: Fatigue. She was exhausted.
  • Clinical Signs: She was wearing a thick jacket in my office… in the middle of a Texas July.
  • Other Symptoms: She was constipated, and her hair was falling out in clumps.

Her labs may have looked “normal,” but she was a walking textbook of hypothyroid symptoms. If her thyroid replacement were truly working, she would not have these symptoms. Clearly, something was not right.

This scenario is the direct result of a historical confluence of events. Synthroid was approved around 1960 based on two simple criteria: it normalized the TSH, and it didn’t cause immediate harm. It was never studied for its ability to resolve the clinical symptoms of hypothyroidism. Around the same time, the ultra-sensitive TSH assay was developed and quickly became the “gold standard” lab test.

Medical schools and residency programs immediately adopted this new paradigm: Diagnose with TSH, treat with Synthroid, and monitor with TSH. This simplistic loop became dogma. The patient’s well-being became secondary to achieving a “normal” lab number. This is a fundamental flaw in modern endocrinology, and it’s leaving millions of patients to suffer unnecessarily.

Redefining Hypothyroidism: A Deeper Look at T3 and T4

To fix this problem, we must first redefine it. The conventional definition of hypothyroidism is based on a lab test. A functional and more accurate definition focuses on the body’s physiological state.

  • Type 1 Hypothyroidism: This is a production problem. The thyroid gland itself is not producing enough hormone. This can be due to surgical removal, radioactive iodine ablation, autoimmune destruction (Hashimoto’s disease), or glandular burnout from chronic stress.
  • Type 2 Hypothyroidism: This is a conversion problem. The body is unable to effectively convert the inactive storage hormone (T4) into the active, usable hormone (T3). This is where the standard T4-only treatment model fails.
  • Type 3 Hypothyroidism: This is a receptor issue in which cellular receptors become resistant to thyroid hormone, often due to inflammation or illness.

The thyroid gland produces a hormone called thyroxine (T4), which contains four iodine atoms. To become metabolically active, it must lose one iodine atom to become triiodothyronine (T3). T3 has five times the affinity for the thyroid receptor as T4. This means T3 is the hormone that does the heavy lifting. T4 is simply the raw material we store to make T3 whenever we need it. You live off your T3.

The Critical Flaw of TSH Testing and Deiodinase Dysfunction

The TSH test was designed as a screening test for an asymptomatic population to see if they are at risk for a thyroid condition. The inventor of the assay himself stated it was never intended to be used to monitor or guide therapy for a treated patient. So why is it the cornerstone of modern treatment? Because it makes the lab reports look good, providing a false sense of security for practitioners while patients remain unwell.

A pivotal study published by Escobar-Morreale et al. (1997) shed light on this discrepancy. Researchers discovered that the concentration of T3 varied significantly in different tissues throughout the body—the liver, kidneys, and muscles. But there was one place where T3 levels remained stable, even when they were low everywhere else: the brain.

This is because the brain and pituitary gland exhibit a unique, highly concentrated expression of the enzyme deiodinase type 2 (D2). This enzyme is responsible for converting T4 into the active T3. The rest of your body—the periphery—also uses D2, but a host of common stressors can downregulate its activity there while leaving it untouched in the pituitary.

What does this mean? It means your pituitary gland—the very organ that produces TSH—lives in a “T3 bubble,” isolated from the reality of what’s happening in the rest of your body. Your muscles, liver, and fat cells can be starving for T3, but your brain’s T3 level can remain perfectly normal. Consequently, your pituitary sees no problem and keeps the TSH level low and “normal.” Your pituitary gland has no idea what the T3 level is in your big toe, and TSH cannot tell us. This is why a patient can have a “perfect” TSH and still feel terrible.

The Roadblock: Reverse T3 and Poor Conversion

The body has a protective buffer system. Under conditions of stress, inflammation, illness, or nutrient deficiency, the body can divert T4 down a different path. Instead of converting to active T3, it uses a different enzyme, deiodinase type 3 (D3), to convert T4 into an inactive form called Reverse T3 (rT3).

Reverse T3 has the same shape as active T3, allowing it to fit into the thyroid receptor. However, it is a dud. It doesn’t turn the engine on. Instead, it sits there, blocking active T3 from getting to the receptor.

When you give a patient a large dose of T4, especially if they have underlying inflammation or stress, their body often perceives it as a threat. To protect itself from becoming overstimulated, it down-regulates D2 (making less active T3) and up-regulates D3 (making more inactive Reverse T3). The result? The patient’s TSH goes down, their labs look “good,” but their symptoms get worse because their cells are being flooded with an inactive blocker hormone.

A landmark study from Israel beautifully outlines the myriad factors that impair the conversion of T4 to T3:

  • Psychological and Physical Stress: High cortisol is a potent inhibitor.
  • Insulin Resistance and Diabetes: Poor blood sugar control disrupts thyroid function.
  • Inflammation: Cytokines from injury, infection, or chronic disease impair deiodinase enzymes.
  • Autoimmune Disease: Conditions such as Hashimoto’s cause chronic inflammation.
  • Nutrient Deficiencies: Deficiencies in key minerals like iron (ferritin) and selenium are critical cofactors for deiodinase enzymes.
  • Aging: The natural process of aging reduces conversion efficiency, as noted by Duntas & Biondi (2011).

Considering this list, it’s clear that the vast majority of people are not converting T4 to T3 optimally, creating an epidemic of subclinical, functional hypothyroidism.

The Heart of the Matter: Low T3 Syndrome and Cardiovascular Risk

The medical field that has most urgently recognized the danger of this condition is cardiology. An overwhelming body of research now links Low T3 Syndrome directly to poor outcomes in cardiovascular disease. A landmark study by Iervasi et al. (2003) found that in patients with heart disease, a low T3 level was a strong prognostic predictor of death, whereas TSH had no predictive value.

Why is this the case? The myocardium, or heart muscle, is exquisitely sensitive to T3. It relies on adequate T3 for proper contractility, rhythm, and overall function. When serum T3 is low, the heart is essentially starved of its primary metabolic fuel. Historically, how did patients with profound, untreated hypothyroidism die? Almost universally from cardiovascular events. A healthy Free T3 level is a critical component of cardiovascular protection. Patients in the lower part of the lab reference range can have a 33% to 66% higher risk of all-cause and cardiovascular mortality compared to those in the upper range (Pingitore, Iervasi, & Chopra, 2008).

The Problem with “Normal”: Redefining Lab Reference Ranges

This brings me to a fundamental problem in conventional medicine: our reliance on statistically “normal” reference ranges. Let’s say the lab reference range for Free T3 is 2.2 to 4.2 pg/mL. A patient comes to me with a level of 2.3 pg/mL. They have been told their thyroid is “normal.” Yet, they are exhausted, their hair is falling out, and they can’t lose weight.

What does being in the 10th percentile of the reference range truly mean? It means 90% of the population has more of this vital, energy-giving hormone than you do. Does that sound optimal? Of course not. My approach is to move patients from the bottom of the range to a more optimal position, typically aiming for the top quartile (75th percentile and above). I am not treating a lab number; I am treating a patient.

A Modern, Evidence-Based Treatment Protocol

So, how do we put all this knowledge into practice? Here is the approach I use, which is grounded in the latest research and my clinical experience.

1. Comprehensive Lab Testing

A TSH-only screen is inadequate. I order a full panel that includes TSH, Free T4, Free T3, and Thyroid Antibodies (TPO and TgAb). If a patient is on T4-only medication and still has symptoms, I always order a Reverse T3 (RT3) test. This panel gives us the complete picture.

2. Choosing the Right Medication

The evidence and patient satisfaction surveys point to a clear conclusion: T4-only therapy is not effective for a significant portion of the population. A 2018 online survey of over 12,000 thyroid patients found that those taking Natural Desiccated Thyroid (NDT), which contains both T4 and T3 (such as NP Thyroid or Armor Thyroid), reported significantly higher satisfaction with their treatment (Peterson et al., 2018).

NDT is derived from porcine thyroid glands and contains T4 and T3 in a ratio very similar to the human thyroid. It provides the body with the active hormone it needs directly, bypassing potential conversion issues. When transitioning a patient from a synthetic T4 medication, I use a careful overlap protocol to allow the body to acclimate smoothly.

3. Standardizing Lab Draws and Dosing

T3 has a very short half-life of about 18-24 hours. To obtain meaningful and consistent data, testing must be standardized. I instruct all my patients to have their blood drawn five to six hours after taking their morning dose. This provides us with a consistent point on the absorption curve.

For my patients with Type 1 hypothyroidism—those without a functioning thyroid—a significant breakthrough has been the introduction of a second, afternoon dose of NDT. Because of T3’s short half-life, a single morning dose often leads to a “crash” by 3 or 4 p.m. By splitting their total daily dose, we maintain a more stable level of active T3, transforming their energy and quality of life.

The Critical, Overlooked Role of Iodine

I cannot overstate the importance of iodine for thyroid health and overall well-being. The Recommended Dietary Allowance (RDA) in the U.S. is a mere 150 micrograms, an amount established simply to prevent goiter, not to promote optimal health. In stark contrast, the average daily intake of iodine in Japan is over 13 milligrams (13,000 micrograms), primarily from seaweed. The correlation with cancer rates is alarming; Japan has significantly lower rates of breast and prostate cancer. As Dr. David Brownstein explains in his book, Iodine: Why You Need It, Why You Can’t Live Without It, this is likely not a coincidence.

Iodine is essential not just for the thyroid but for breast tissue, the prostate, ovaries, and every cell in the body. When you begin supplementing an iodine-deficient person, TSH will temporarily rise. This is the body’s intelligent response to produce more sodium-iodide symporters (NIS)—the gateways that pull iodine into the cells. An uninformed practitioner might see this TSH spike and wrongly conclude that the iodine is harmful. This is why I tell my patients we will not check a TSH level for at least nine months after starting iodine therapy. Free T3 and the patient’s symptoms are our true guides.

Integrative Chiropractic Care: The Neurological Connection

As a Doctor of Chiropractic (DC), I view the body through the lens of the nervous system as the master controller of all other systems, including the endocrine system. The connection among the spine, the nervous system, and thyroid function is a critical yet often-overlooked piece of the puzzle.

The thyroid gland receives its nerve supply from the cervical spine. Misalignments, or vertebral subluxations, in this area can interfere with the nerve signals traveling between the brain and the thyroid. This can disrupt the delicate feedback loop of the hypothalamic-pituitary-thyroid (HPT) axis.

How Chiropractic Fits In:

  • Restoring Nerve Function: Through specific, gentle chiropractic adjustments, we can correct subluxations in the cervical spine. This restores proper nerve flow, ensuring the brain and thyroid can communicate effectively. In my clinic, I have observed that patients receiving regular chiropractic care often see improvements in their thyroid function.
  • Reducing Systemic Stress: The chiropractic adjustment has a powerful effect on the autonomic nervous system, helping to shift the body from a “fight-or-flight” (sympathetic) state to a “rest-and-digest” (parasympathetic) state. Chronic stress elevates cortisol levels, which inhibit the conversion of T4 to T3. By modulating the stress response through chiropractic care, we create a more favorable hormonal environment for optimal thyroid function.
  • Holistic Support: Integrative chiropractic care encompasses nutritional counseling, lifestyle recommendations, and stress management techniques, all of which are foundational to supporting endocrine health.

By integrating chiropractic adjustments with functional medicine protocols, we address both the biochemical and neurological aspects of thyroid dysfunction, providing a truly comprehensive and powerful path to healing. Ultimately, our goal is not just to fix a lab value. It is to listen to our patients, to understand the deep physiological imbalances at play, and to use every evidence-based tool at our disposal to restore health and change lives.

References

Brownstein, D. (2014). Iodine: Why you need it, why you can’t live without it (5th ed.). Medical Alternatives Press.

Duntas, L. H., & Biondi, B. (2011). The aging thyroid: a challenge for the clinician. Nature Reviews Endocrinology, 7(9), 558–560. https://www.nature.com/articles/nrendo.2011.83

Escobar-Morreale, H. F., Obregón, M. J., Escobar del Rey, F., & Morreale de Escobar, G. (1997). Tissue-specific patterns of changes in 3,5,3′-triiodothyronine concentrations in hypothyroid rats. Endocrinology, 138(6), 2494-2503. https://doi.org/10.1210/endo.138.6.5186

Guo, T., Wang, Y., Zhang, Y., Ma, J., & Wang, F. (2022). Lower free triiodothyronine levels are associated with major depressive disorder and its symptom severity. Psychoneuroendocrinology, 146, 105952. https://doi.org/10.1016/j.psyneuen.2022.105952

Iervasi, G., Pingitore, A., Landi, P., Raciti, M., Ripoli, A., Scarlattini, M., L’Abbate, A., & Donato, L. (2003). Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation, 107(5), 708–713. https://www.ahajournals.org/doi/10.1161/01.cir.0000048039.63811.23

Peeters, R. P., Wouters, P. J., van Toor, H., Kaptein, E., Visser, T. J., & Van den Berghe, G. (2003). Serum 3,3′,5′-triiodothyronine (rT3) and 3,5,3′-triiodothyronine/rT3 are prognostic markers in critically ill patients and are associated with postmortem tissue deiodinase activities. The Journal of Clinical Endocrinology & Metabolism, 88(10), 4559–4565. https://academic.oup.com/jcem/article/88/10/4559/2845213

Peterson, S. J., Cappola, A. R., Castro, M. R., Dayan, C. M., Farwell, A. P., Hescox, M., & … Bianco, A. C. (2018). An online survey of hypothyroid patients demonstrates prominent dissatisfaction. Thyroid, 28(6), 707–721. https://doi.org/10.1089/thy.2017.0681

Pingitore, A., Iervasi, G., & Chopra, I. J. (2008). The role of thyroid hormone in the heart. Journal of Clinical Endocrinology & Metabolism, 93(6), 1957–1964.

Shakir, M. K., Brooks, B. A., & Crooks, L. A. (2007). The significance of a suppressed TSH in hypothyroid patients on levothyroxine. Endocrine Practice, 13(1), 16-20. https://doi.org/10.4158/EP.13.1.16

Starr, M. (2005). Hypothyroidism Type 2: The epidemic. Mark Starr Trust.

Woeber, K. A. (2002). Levothyroxine therapy and serum free thyroxine and free triiodothyronine concentrations. Journal of Endocrinology and Metabolism, 87(9), 3986-3990. https://doi.org/10.1210/jc.2002-020580

A Smarter Path to Hormonal Health and Vitality

A Smarter Path to Hormonal Health and Vitality

A Smarter Path to Hormonal Health and Vitality
Health: doctor visit with patient, medical exam, hospital visit, and conversation about bioidentical hormone replacement therapy.

Abstract

Welcome. As a clinician with a diverse background in chiropractic, advanced practice nursing, and functional medicine, I am deeply committed to an integrative, evidence-based approach to health. This educational post will guide you through the intricate and often misunderstood world of hormones, debunking long-held myths and presenting a modern, holistic paradigm for wellness. We will critically re-examine the flawed Women’s Health Initiative (WHI) study, exposing how the use of synthetic hormones and improper delivery systems created a legacy of fear. We will explore the profound differences between bioidentical progesterone and synthetic progestins and present compelling data that vindicates estrogen, revealing its protective role against breast cancer. This journey will also dismantle myths surrounding testosterone, clarifying its crucial role in both men and women for cognitive function, mental health, cardiovascular wellness, and pain management. We will explore the physiological underpinnings of bone health, contrasting outdated bisphosphonate therapies with a superior, hormone-centric approach. Throughout this discussion, I will integrate the principles of integrative chiropractic care, demonstrating how restoring structural and neurological integrity is foundational to achieving optimal hormonal balance and preventing the chronic diseases of aging. My goal is to empower you with knowledge, moving from fear and misinformation to clarity and confidence in your health decisions.

Unraveling the Women’s Health Initiative: A Critical Re-Examination

Let’s begin by asking a fundamental question: Why are you here, reading this today? Perhaps it’s because the conventional health approaches you’ve encountered haven’t provided the answers or the well-being you’re seeking. This is a common story in my practice. People feel unwell, unheard, and confused by conflicting information, especially when it comes to hormones.

My journey and yours often start with a desire to understand the “why.” This is particularly true when we look at the history of hormone replacement therapy (HRT). Let’s travel back to the pivotal Women’s Health Initiative (WHI) study, a trial whose initial results, reported in 2002, radically altered our perception of hormones and left a legacy of fear that persists to this day.

But what if the study’s foundation was flawed from the start? Let’s consider a hypothetical. What if the WHI had used 17-beta estradiol delivered via a non-oral route, like a patch, instead of oral conjugated equine estrogens (Premarin)? And what if they had used bioidentical progesterone instead of a synthetic progestin like medroxyprogesterone acetate (Provera)?

The Critical Importance of Delivery Systems and Molecular Structure

To understand why this distinction is so crucial, we must look at our physiology. When you take a hormone in an oral pill form, it undergoes first-pass metabolism in the liver.

  • Portal Circulation: Blood from your intestines goes directly to the liver through the portal vein.
  • Liver Metabolism: The liver works hard to process this concentrated dose of the oral hormone. In response, it produces other substances, including an increased amount of clotting factors.
  • Increased Clotting Risk: This is precisely why oral estrogen, found in medications like birth control pills and Premarin, is associated with an elevated risk of blood clots.

One of the most important benefits of estrogen is its cardioprotective effect. However, administering it orally simultaneously increases clotting factors, effectively canceling that benefit, since most heart attacks and strokes involve clot formation. The WHI concluded that estrogen didn’t help, but the reality is that they were using the wrong molecule (conjugated equine estrogens) and the wrong delivery system (oral). Had the study used 17-beta estradiol—the exact molecule our bodies are designed to use—and administered it transdermally, bypassing intensive liver metabolism, the outcomes would have been dramatically different.

Now, let’s look at progesterone. Has natural, bioidentical progesterone ever been shown to increase the risk of breast cancer in any credible study? The answer is a resounding no. The WHI used a synthetic progestin, Provera. We wouldn’t be having this conversation today if we had used the correct hormone molecules and delivery systems. The standard of care would be clear: as soon as a woman enters menopause, she should begin estrogen and progesterone therapy for the long-term health of her heart, bones, and brain.

The Lasting Impact and Ultimate Vindication of Estrogen

I was in private practice when the 2002 WHI results were published in the Journal of the American Medical Association (JAMA) and splashed across the cover of TIME magazine. Fear sells. The report, titled “The Truth About Hormones,” scared millions of women. I had to hire an additional staff member just to field panicked calls from patients wanting to stop their hormones.

In my clinical practice at our Chiropractic & Functional Medicine Clinic, I see the downstream effects every day. How many women today are suffering from cognitive decline, osteoporosis, and heart disease that could have been mitigated? Depriving an entire generation of women of protective estrogen has had devastating consequences.

The story gets even more compelling over time. Follow-up reports on the same WHI cohort have been nothing short of vindicating for estrogen.

  • An 18-year follow-up published in JAMA stated, “Estrogen plus progestin was not associated with increased all-cause, cardiovascular, or cancer mortality…” (Manson et al., 2017). Essentially, the researchers were saying, “Never mind.”
  • A 2020 study, also in JAMA, delivered a bombshell. Women in the estrogen-only arm for about seven years had a lower incidence of breast cancer and were less likely to die from breast cancer over their lifetimes (Chlebowski et al., 2020).

Let that sink in. Estrogen is the only medicine in history shown in a prospective, randomized, placebo-controlled, long-term trial to reduce the chance of both getting breast cancer and dying from it. And this result was with Premarin, a “dirty” estrogen. Imagine the protective power of bioidentical 17-beta estradiol.

Understanding Progesterone vs. Progestins: A Critical Distinction

It is critically important to distinguish between progesterone and progestins. They are not the same, and this confusion is at the heart of much of the misinformation surrounding HRT.

  • Progesterone (P4): This is the natural, bioidentical hormone our bodies produce. It has a specific, beneficial molecular structure.
  • Progestins: These are synthetic compounds designed to mimic some of the effects of progesterone. Examples include medroxyprogesterone acetate and norethindrone acetate. They have different molecular structures and vastly different metabolic effects.

When I see a new study claiming “hormone replacement therapy” causes a health issue, the first thing I do is look at the abstract to identify the molecules used. Invariably, the culprit is a synthetic progestin.

Progesterone’s role is often tragically minimized, especially in women who have had a hysterectomy. The conventional thinking, “No uterus, no need for progesterone,” is a fundamentally flawed and harmful perspective. It ignores the progesterone receptors in the brain, bones, and cardiovascular system. In my clinical practice, every menopausal patient is on progesterone at some point. If a woman presents with insomnia, I frequently initiate treatment with progesterone, as it is unequivocally the most effective remedy for insomnia in menopausal women.

A crucial point of caution: progesterone cream is not sufficient for uterine protection. Progesterone is a large molecule that does not absorb well through the skin to achieve adequate systemic blood levels. If a uterus is present, progesterone must be delivered systemically—orally, sublingually, or as a vaginal suppository—to ensure the uterine lining is protected from the proliferative effects of unopposed estrogen (Hargrove et al., 1989).

The Menstrual Cycle: A Symphony of Hormones

To appreciate the role of hormones, we must understand their natural rhythm. The menstrual cycle is a beautiful, synergistic dance, not a battle for dominance.

  1. Follicular Phase (First Half): As a dominant follicle grows, it produces estrogen, which causes the uterine lining (endometrium) to thicken.
  2. Luteal Phase (Second Half): After ovulation, the corpus luteum produces progesterone. Progesterone’s role is to stabilize the endometrium, halting estrogen-driven proliferation and preparing the tissue for implantation.
  3. Menstruation: If implantation does not occur, the drop in progesterone triggers the shedding of the uterine lining.

It’s a mistake to say that progesterone “opposes” estrogen. They work synergistically as a team. Studying a hormone in isolation will never provide a complete understanding of its effects.

Testosterone: A Human Hormone Essential for All

One of the most persistent myths is that testosterone is exclusively a male hormone. Let’s set the record straight: testosterone is a human hormone.

  • A woman produces more testosterone over her lifetime than she does estrogen.
  • The androgen receptor is located on the X chromosome, which every individual possesses.
  • Ignoring testosterone deficiency in women, especially after a hysterectomy with ovary removal, is a grave oversight. We are taking out three essential hormones (estrogen, progesterone, and testosterone) and often replacing only one poorly.

In my practice, optimizing testosterone is crucial. It’s a key factor in managing the number one symptom of menopause: pain. Joint, bone, and muscle pain are the body’s first signals of a critical hormonal deficit.

Debunking the Myth: Testosterone and Prostate Cancer

For decades, physicians have feared that testosterone therapy is like “adding fuel to the fire” of prostate cancer. Dr. Abraham Morgentaler of Harvard traced this myth to a single, 100-year-old study of only two men. His career has been dedicated to dismantling this myth with rigorous science.

His research showed that low testosterone, not replacement therapy, is an independent risk factor for developing prostate cancer. This led to the Prostate Saturation Model. Dr. Morgentaler found that prostate androgen receptors become fully saturated at a testosterone level of around 200 ng/dL. This means that for a man with a baseline level of 350 ng/dL, optimizing his level to 950 ng/dL adds zero additional testosterone to his prostate. The receptors are already full.

The current consensus is that if a man has been successfully treated for prostate cancer and shows no evidence of recurrence, testosterone therapy can and should be initiated immediately to restore his quality of life.

Beyond “Normal”: The Power of Hormone Optimization

One of the most profound shifts in modern functional medicine is the move from the “normal range” to the “optimal range.” A lab’s reference range is just a statistical average; it says nothing about what is healthy.

A study on dementia found that men with testosterone levels in the lowest quintile had an 80% higher risk of developing dementia than men in the highest quintile (Yeap et al., 2021). A man with a “low normal” level of 325 ng/dL has a significantly higher risk than a man at an optimal 850 ng/dL. There is only suboptimal and optimal.

My goal is to restore a patient’s hormone levels to the upper quartile of the range for a young, healthy adult—a level that is protective against disease and promotes vitality.

The Receptor Model of Cancer and the Protective Role of Hormones

To understand why old fears were misplaced, we must look at the cellular level. The Receptor Model for Cancer explains that hormones exert their effects by binding to specific receptors. The problem arises with synthetic molecules like progestins, which can block protective receptor pathways, effectively removing the brakes on cell growth.

This is what happened in the WHI. The synthetic progestin blocked protective pathways, leading to an observed increase in breast cancer. It wasn’t the estrogen; it was the progestin.

In stark contrast, compelling evidence shows that testosterone has anti-inflammatory and anti-proliferative (anti-cancer) effects in breast tissue. Dr. Rebecca Glaser, a breast cancer surgeon, has published extensively on this.

  • A massive Nurses’ Health Study followed nearly 30,000 nurses for 24 years. It found that women who had their ovaries removed (inducing surgical menopause) had a significantly higher risk of all-cause mortality, heart disease, and lung cancer compared to those who conserved their ovaries (Parker et al., 2013). Our natural hormones provide powerful, lifelong protection.

Rethinking Osteoporosis: Hormones for Bone Health

The conventional approach to osteoporosis, using drugs like bisphosphonates, is deeply flawed. These drugs work by blocking osteoclasts, the cells that break down old bone. This is like paving over a road full of potholes without clearing out the crumbling asphalt. You accumulate old, weak, brittle bone that may look denser on a scan but is not structurally sound.

The true key is promoting healthy bone remodeling, and hormones are the master regulators. A landmark study showed that patients on hormone pellet therapy experienced an average 8.3% increase in bone density per year. This vastly outperforms bisphosphonates (1-2% annual increase). By restoring hormonal levels of estrogen and testosterone, we effectively turn back the clock on skeletal health.

Testosterone and the Heart: A Cardiologist’s Best Friend

One of the most dangerous myths is that testosterone is bad for the heart. This scare originated from a thoroughly debunked 2016 VA study that used a flawed high-risk population and manipulated data to reverse its own raw findings.

The scientific reality is that low testosterone is an independent risk factor for cardiovascular disease. Optimal testosterone is a cardiologist’s best friend because it:

  • Improves endothelial function, keeping arteries smooth.
  • Increases arterial elasticity, helping regulate blood pressure.
  • Enhances insulin sensitivity, a primary driver of heart disease.
  • Exerts anti-inflammatory effects, quelling the inflammation that underlies heart attacks.

Integrative Chiropractic Care: Restoring Foundational Health

This is where the principles of integrative chiropractic care and functional medicine become so vital. The body is an interconnected system where structure governs function. Hormonal balance cannot be fully achieved if the underlying neurological and structural systems are compromised.

  • Nervous System Regulation: The endocrine system is under the direct control of the nervous system. Chiropractic adjustments correct spinal misalignments (subluxations), restoring proper nerve flow between the brain and the endocrine glands. This optimizes the function of the hypothalamic-pituitary-adrenal-ovarian (HPAO) axis, the master communication network governing hormone production.
  • Stress Reduction: Adjustments can shift the autonomic nervous system from a dominant “fight-or-flight” (sympathetic) state to a more relaxed “rest-and-digest” (parasympathetic) state. This is crucial because chronic stress elevates cortisol, which can disrupt the entire endocrine system and steal the building blocks for sex hormone production.
  • Holistic Assessment: As a Doctor of Chiropractic, I have a comprehensive understanding of the situation. Low back pain may be connected to fatigue, low mood, systemic inflammation, and hormonal imbalance. This integrative perspective allows me to educate patients on the connections between their spine, nervous system, and hormonal health.

By combining evidence-based hormone optimization with the foundational principles of chiropractic care, we address the root cause of dysfunction. We don’t just replace a missing hormone; we restore the body’s innate intelligence and create a synergistic effect for true, resilient health. This is the future of healthcare—a proactive, personalized, and integrative approach that empowers you to live a longer, healthier, and more vibrant life.

References

Chlebowski, R. T., Anderson, G. L., Aragaki, A. K., et al. (2020). Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials. JAMA, 324(4), 369–380.

Hargrove, J. T., Maxson, W. S., Wentz, A. C., & Burnett, L. S. (1989). Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstetrics and Gynecology, 73(4), 606–612.

Manson, J. E., Aragaki, A. K., Rossouw, J. E., et al. (2017). Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women’s Health Initiative Randomized Trials. JAMA, 318(10), 927–938.

Parker, W. H., Feskanich, D., Broder, M. S., Chang, E., Shoupe, D., Farquhar, C. M., Berek, J. S., & Manson, J. E. (2013). Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstetrics and Gynecology, 121(4), 709–716.

Yeap, B. B., Flicker, L., Xiao, J., Norman, P. E., Hankey, G. J., Almeida, O. P., & Almeida, O. (2021). Associations of sex hormones with incident dementia and cognitive decline in older men: The Health in Men Study. The Journal of Clinical Endocrinology & Metabolism, 106(4), 1042-1054.

Hormone Optimization for Wellness & Women’s Health

Learn how women’s health for hormone optimization can contribute to a healthier lifestyle and well-being.

Abstract

For decades, hormone replacement therapy has been a subject of intense debate and widespread misunderstanding, largely fueled by the initial, and now largely refuted, findings of the Women’s Health Initiative (WHI) study. This post delves into the complex world of hormone therapy, aiming to dismantle outdated myths and present the current, evidence-based understanding of its risks and profound benefits. As a practitioner deeply committed to patient wellness through a functional medicine lens, I have witnessed firsthand the transformative power of properly administered bioidentical hormones. Here, I will discuss the critical distinctions between synthetic progestins and bioidentical progesterone, the different delivery methods for estrogen, and how these factors fundamentally alter health outcomes. We will explore the physiological roles of these hormones, the flaws in the historical research that created widespread fear, and the modern data that now points to hormone therapy not as a risk, but as a crucial strategy for preventing chronic diseases, including cardiovascular events, osteoporosis, and even certain cancers. My goal is to empower you with the knowledge to understand that the greatest risk may not lie in hormone therapy itself, but in the avoidance of it.

Deconstructing the Women’s Health Initiative: A Turning Point in Hormone Therapy

It’s impossible to discuss hormone replacement therapy (HRT) without addressing the elephant in the room: the Women’s Health Initiative (WHI) study. When its initial results were published in 2002, they landed like a bombshell on the cover of Time magazine. The ensuing panic was immense. In my practice, the phone rang incessantly. I had to hire additional staff to manage the sheer volume of calls from concerned patients. Ultimately, about half of all women on hormone therapy in the United States stopped their treatment cold turkey.

Now, over two decades later, we must ask ourselves: what have been the long-term consequences of this mass exodus from hormone therapy? Have we seen the promised reductions in chronic disease?

  • Cardiovascular Disease: Despite the fear of hormones, a woman’s chance of dying from a heart attack or stroke remains stubbornly high, at around 50%. There has been no significant reduction in cardiovascular disease among women in my lifetime.
  • Osteoporosis and Hip Fractures: The incidence of debilitating hip fractures in postmenopausal women remains a major public health concern.
  • Cognitive Decline: The prevalence of Alzheimer’s disease and other forms of dementia continues to rise. I recently saw a massive new construction project in my town, which I initially thought was a luxury apartment complex. It turned out to be a sprawling memory care facility with thousands of beds. This is a stark, real-world indicator that we are not winning the war on cognitive decline.

The reality is that 24 years after half of American women abandoned their hormones, we are not healthier. In fact, we are arguably worse off.

The Flawed Science of the WHI Study

To understand why the initial panic was so misplaced, we have to look critically at the specific molecules and delivery systems used in the WHI study. The study did not use the hormones naturally produced by the human body. Instead, it used:

  1. Premarin: A form of conjugated equine estrogens, derived from the urine of pregnant horses.
  2. Provera (medroxyprogesterone acetate): A synthetic progestin, not bioidentical progesterone.
  3. Oral Delivery: Both substances were administered as pills.

This is a critical point. Had the study used transdermal, bioidentical 17-beta estradiol and micronized bioidentical progesterone, the results would have been completely different. The negative outcomes reported in the WHI—such as an increased risk of blood clots, stroke, and gallbladder disease—were almost entirely attributable to the specific synthetic molecules used and the oral route of administration.

When you swallow an estrogen pill, it undergoes a “first-pass metabolism.” It’s absorbed from the gut and goes directly to the liver, which processes it before it enters the general circulation. This process significantly increases the liver’s production of clotting factors, thereby increasing the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE). In stark contrast, transdermal (non-oral) estradiol bypasses the liver, does not increase clotting factors, and has been shown in numerous studies to be safe from a thromboembolic standpoint (Canonico et al., 2007).

The Retraction and the Vindication of Estrogen

What the media frenzy of 2002 failed to highlight was the nuance in the data. Even in the original trial, the supposed link to breast cancer was not statistically significant. Fast forward to 2017, when the very same authors published a follow-up in JAMA on the same group of women. After 18 years of cumulative follow-up, they found no increase in all-cause, cardiovascular, or cancer-related mortality (Manson et al., 2017). In essence, they admitted their initial conclusions were wrong. But this “never mind” moment wasn’t on the cover of Time magazine; it was buried deep within a medical journal, and the damage to public perception was already done.

It gets even more compelling. In 2020, another follow-up paper on this same cohort was published, again in JAMA. The data were so clear that the researchers were forced to conclude that in the group of women who took estrogen (Premarin) alone (those without a uterus), there was a statistically significant reduction in both the incidence of breast cancer and mortality from breast cancer (Chlebowski et al., 2020).

Let that sink in. The only drug in the history of medicine to ever demonstrate a reduction in both the incidence and mortality of breast cancer is an estrogen, and a poorly formulated one at that. Why isn’t this front-page news? Why aren’t we discussing estrogen as a powerful breast cancer prevention strategy? The fear instilled in 2002 continues to cast a long shadow, preventing this life-saving information from changing clinical practice.

The Real Risks: Hormone Avoidance

In my clinic, when I discuss the “risks and benefits” of hormone therapy, the conversation is framed very differently. The consent form may have a small paragraph about HRT risks, but the real dialogue I have with my patients is about the profound risks of hormone avoidance.

What does it mean to “do menopause naturally”? It means accepting a future with a sharply increased risk of:

  • Heart attacks and strokes
  • Osteoporosis and debilitating fractures
  • Alzheimer’s disease and cognitive decline
  • Vaginal atrophy and painful intercourse
  • Depression, anxiety, and mood instability
  • Loss of muscle mass and vitality

Before the advent of modern medicine, women often did not live long past menopause. Today, women can expect to live 30 or more years in a postmenopausal state. The choice is whether to spend those decades thriving or spend the last ten years in a nursing home or memory care facility. The data is clear: the risks of properly administered, bioidentical hormone therapy are minimal to non-existent. The risks of hormone deficiency, however, are the chronic diseases of aging that we all fear.

The Symphony of Hormones: Understanding Receptors

The ancient Greeks used the word “”ormone” to mean “to set in motion.” It’s a perfect description. Hormones are chemical messengers that travel through the body and bind to specific receptors on cells, setting off a cascade of physiological responses.

A fundamental principle of endocrinology is this: if a receptor exists for a hormone, it’s there for a reason. The cell expects that hormone to be present and to deliver its message. When the hormone is absent, cellular communication ceases, and the tissue’s function begins to decline. This cannot be a healthy state.

  • Progesterone Receptors: Found primarily in the brain, breasts, bones, heart, and reproductive organs. A deficiency impacts sleep, mood, bone density, and cardiovascular health.
  • Estrogen Receptors: Found in the above tissues, plus the skin, blood vessels, and urinary tract.
  • Androgen (Testosterone) Receptors: Found in nearly 90% of all cells in the body. Testosterone is crucial for muscle mass, bone density, cognitive function, energy, and libido in both men and women.
  • Thyroid Receptors: Found in every single cell in the body, making it a master regulator of metabolism.

People often ask me which hormone is the “most important.” The truth is, they work synergistically. I often use the analogy of a cake and frosting. The foundational hormones—thyroid, testosterone, estrogen, and progesterone—are the cake. You must get the cake right first. Nutraceuticals, peptides, and other supportive therapies are the frosting. They are wonderful additions, but they can’t fix a poorly made cake. Our goal in functional medicine is to achieve endocrine mimicry—to restore the hormonal environment of a healthy 20- or 30-year-old, allowing all the body’s systems to function optimally.

Progesterone vs. Progestins: A Critical Distinction

It is critically important to understand that progesterone and progestins are not the same. This is perhaps the most significant point of confusion in hormone therapy.

  • Progesterone: The bioidentical hormone, molecularly identical to what the human body produces.
  • Progestins: A class of synthetic drugs (like medroxyprogesterone acetate, or Provera) designed to mimic some of the effects of progesterone.

Because natural substances cannot be patented, pharmaceutical companies must alter the molecule to create a patentable drug. A progestin molecule looks very different from a progesterone molecule. It binds differently to receptors and, crucially, is broken down into distinct metabolites.

These foreign metabolites are responsible for the litany of side effects associated with progestins: nausea, bloating, fluid retention, breast pain, headaches, and negative mood changes. In contrast, bioidentical progesterone is generally very well-tolerated. Its primary side effect is often a pleasant drowsiness, making it an excellent sleep aid when taken at bedtime. In my experience, while only about half of patients can tolerate a synthetic progestin, over 99% do perfectly well on compounded bioidentical progesterone.

The Role of Progesterone in a Woman’s Life

Progesterone is not just for protecting the uterus. Its most important function throughout the body is stabilization. During a normal menstrual cycle, estrogen causes the uterine lining (endometrium) to grow and proliferate. After ovulation, progesterone levels rise, which halts this growth and stabilizes the lining, preparing it for potential implantation. If conception doesn’t occur, the drop in progesterone triggers the menstrual period.

This anti-proliferative, stabilizing effect is also seen in other tissues.

  • Brain: Progesterone has calming, neuroprotective effects. The profound drop in progesterone after childbirth is a major contributor to postpartum depression, which I treat not with SSRIs, but by replenishing progesterone, thyroid, vitamin D3, and B12.
  • Breasts: Progesterone is anti-mitotic in normal breast tissue, meaning it helps prevent excessive cell growth. It is a key therapy I use for patients with painful, fibrocystic breasts. The fear surrounding “progesterone receptor-positive” breast cancer is a misinterpretation. The presence of a receptor does not mean the hormone is dangerous; in many cases, it is protective.

Clinical Pitfalls in Progesterone Prescribing

Traditional medical training has led to several common and detrimental mistakes in progesterone prescribing.

  1. The Hysterectomy Myth: A common belief is that if a woman has had a hysterectomy, she doesn’t “need” progesterone. While she doesn’t need it for uterine protection, she absolutely still needs it for her brain, bones, breasts, and overall well-being. Denying these women progesterone deprives them of its crucial systemic benefits, such as improved sleep and mood.
  2. Relying on Progesterone Creams: Progesterone is a large molecule. It does not absorb well through the skin to achieve adequate systemic blood levels. Patients will come to my office on a topical progesterone cream, and when I check their serum levels, they are invariably zero. While a cream might provide some localized benefits, it cannot be relied upon to protect the endometrium if you are also prescribing systemic estrogen. This is a critical point of medical-legal liability. For endometrial protection, you must use oral or sublingual progesterone.
  3. Ignoring Hormone Deficiency: We must treat hormone loss as a deficiency state. Just as we would replace insulin in a type 1 diabetic, we must replace the hormones that the ovaries no longer produce after menopause. This includes progesterone, regardless of whether a uterus is present.

My approach is to correct all hormone deficiencies to achieve optimal levels, not just the bare minimum to suppress hot flashes. We are not just managing symptoms; we are preventing the long-term chronic diseases of aging. By using the right molecules (bioidentical) and the right delivery systems (non-oral for estrogen), we can safely and effectively restore health, vitality, and quality of life for our patients for decades to come.

References

  • Chlebowski, R. T., Anderson, G. L., Aragaki, A. K., et al. (2020). Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials. JAMA, 324(4), 369–380. https://doi.org/10.1001/jama.2020.9482
  • Canonico, M., Oger, E., Plu-Bureau, G., et al. (2007). Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation, 115(7), 840–845. https://doi.org/10.1161/CIRCULATIONAHA.106.642280
  • Manson, J. E., Chlebowski, R. T., Stefanick, M. L., et al. (2017). Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women’s Health Initiative Randomized Trials. JAMA, 318(10), 927–938. https://doi.org/10.1001/jama.2017.11217

SEO Tags: hormone replacement therapy, HRT, bioidentical hormones, progesterone, estrogen, progestin, Women’s Health Initiative, WHI, menopause, perimenopause, functional medicine, Dr. Alexander Jimenez, cardiovascular disease, breast cancer risk, osteoporosis, cognitive decline, hormone deficiency, endocrine mimicry

Sex Hormone Optimization for Total Body Health

Sex Hormone Optimization for Total Body Health

Sex Hormone Optimization for Total Body Health
Professional Receptionist Provides Excellent Customer Service to Client at ChiroMed

Abstract

Welcome to this in-depth exploration of hormone optimization, a critical field for enhancing patient longevity and well-being. My name is Dr. Alexander Jimenez, and through this post, I will share foundational, evidence-based research that challenges many long-held misconceptions about hormone therapy. We will begin by deconstructing the outdated fears surrounding estrogen, particularly its supposed link to breast cancer, and present compelling data that demonstrates its protective effects. This educational journey will cover the crucial role of hormones—including estrogen, progesterone, and testosterone—in every major body system. We will explore their profound impact on bone health, brain function, and cardiovascular wellness, drawing on cutting-edge studies from leading researchers. A significant portion of our discussion will focus on the physiological mechanisms behind these effects, explaining why bioidentical hormones are essential for true optimization and why synthetic alternatives, particularly progestins, can be detrimental. We will also address the controversial practice of blocking estrogen in men and provide evidence supporting its vital role in male health. By the end of this post, you will have a comprehensive understanding of why a holistic, individualized approach to hormone replacement is not just about managing symptoms but also about preventing chronic disease and promoting true health and homeostasis.

A New Paradigm in Healthcare: Beyond Symptom Management

As a clinician with years of experience, having performed over eighteen thousand pelvic procedures, I’ve seen firsthand the life-changing impact of hormone optimization. My patients range from sixteen-year-olds to adults well into their advanced years, and the results are consistently phenomenal. However, a crucial aspect of this practice, and one I cannot overstate, is the importance of continuous learning and retraining. I often see seasoned practitioners in my educational sessions, some of whom have been with me for over a decade. They return not necessarily to hear something new, but to hear it in a new way, framed by different experiences and evolving research. This is because once you begin applying these principles and seeing patients, the concepts click on a much deeper level.

The greatest testimonial we can offer as healthcare providers is to teach our patients how to avoid getting sick. Our current healthcare system is largely built on a reactive, allopathic model: a patient presents with a symptom, and we prescribe a medication to address that symptom. This weekend, I want to encourage a paradigm shift. Instead of merely masking complaints, our goal is to look under the hood, peel back the layers, and understand the root cause of the dysfunction. Disease is not a normal state of being. Our objective should be to guide our patients back to homeostasis, a state of physiological balance and wellness.

Re-Examining Estrogen: From Misconception to Essential Molecule

Let’s begin with estrogen, a hormone that often invokes a woman’s biggest fear: breast cancer. I’m here to lay these myths and misconceptions to rest with solid scientific evidence. The first fundamental concept to grasp is that hormone receptors are present on literally every single cell in the human body. Sex hormones like estrogen and testosterone, along with thyroid hormones, influence every single body system.

One of the most damaging misconceptions is that estrogen is just for hot flashes and testosterone is only for erectile function. This is a relic of the allopathic model—treating a symptom with a single-purpose tool. I want to shift your perspective entirely. Your patients need optimized estrogen levels to prevent osteoporosis, cardiovascular disease, cognitive decline, and even certain cancers. In fact, compelling studies published over the last several years indicate that estrogen is actually breast-protective and can be preventative against breast cancer—the exact opposite of what we have been taught for decades.

Understanding Hormone Receptors and Their Function

Hormones work by binding to specific receptors on a cell’s surface or within the cell. Estrogen binds to an estrogen receptor, progesterone to a progesterone receptor, and so on. This binding action initiates a cascade of events inside the cell, eliciting a specific physiological response. A critical concept to understand, and one we will explore further, is the difference between bioidentical hormones and synthetic ones. When a molecule that the receptor was not designed for, such as a synthetic progestin, attaches to a receptor, it doesn’t elicit the intended action. Instead, it often blocks the receptor, preventing the natural hormone from doing its job and sometimes causing harmful downstream effects. Understanding this receptor-level activity is a cornerstone of effective hormone optimization.

The Widespread Benefits of Estrogen Optimization

Estrogen’s role extends far beyond managing menopausal symptoms. Its influence is systemic and vital for long-term health.

  • Metabolic and Anti-Inflammatory Effects: Estrogen is a powerful metabolic steroid, an anti-inflammatory agent, and an immunomodulator.
  • Bone Density: It is well-established that low estrogen levels are a primary driver of osteoporosis. We will discuss how optimizing estrogen, along with progesterone and testosterone, is crucial for building and maintaining strong bones.
  • Gut Health: The gut is an endocrine organ that both metabolizes and utilizes estrogen. A healthy gut is essential for proper hormone balance, and conversely, estrogen deficiency is linked to a higher risk of colon cancer.
  • Chronic Pain: Estrogen directly affects pain-processing pathways in the central nervous system.
  • Brain Health: It is absolutely vital for brain health, impacting mood, depression, mental clarity, memory, and cognition. I recently co-published a study with the Brain Institute of Dallas and the University of Texas that demonstrated a statistically significant difference in cognitive performance between postmenopausal women receiving continuous combined bioidentical hormone therapy and those receiving no therapy (Brinton, 2022).
  • Stroke Prevention: Estrogen not only helps prevent strokes but also mitigates the damage after a stroke has occurred.

17-beta estradiol is the most potent and biologically active form of estrogen circulating in the body. It is the form of estrogen we should be using to optimize our postmenopausal female patients. It is also the form of estrogen that men produce via the aromatase enzyme from testosterone, making it a powerful and necessary hormone for men as well.

Deconstructing the Women’s Health Initiative (WHI) Study

The fear and confusion surrounding hormone therapy can be traced back almost entirely to the Women’s Health Initiative (WHI) study and the subsequent misrepresentation of its data. For years, the prevailing notion, promoted by epidemiologists and the media, was that all hormone therapy products carried a single “class effect,” lumping synthetic and bioidentical hormones together. This was a dangerous oversimplification.

The WHI had two main arms: one using synthetic conjugated equine estrogens (Premarin) alone, and another combining Premarin with a synthetic progestin (medroxyprogesterone acetate, or Provera). Here is what the data actually showed:

  • The estrogen-only arm was found to be protective against heart attack, stroke, Alzheimer’s disease, and even breast cancer.
  • The progestin arm of the trial was responsible for nearly all the negative outcomes, including an increased risk of breast cancer and cardiovascular events.

Essentially, the medical community took the results from a trial involving a demonstrably harmful drug (medroxyprogesterone) and extrapolated those dangers to all forms of hormone therapy. It has taken us over 20 years to begin unraveling this misinformation. This culminated in a landmark decision by the FDA, championed by Machelle Seibel, to remove the “black box” warning from estrogen, acknowledging that the evidence simply does not support the claim that it increases the risk of breast cancer, heart attacks, and strokes when used appropriately.

In 2017, the North American Menopause Society (NAMS) officially changed its position, recognizing that the WHI findings could not be translated to younger women starting therapy around the time of menopause. The participants in the WHI were, on average, older (mean age of 63), sicker, and many already had established cardiovascular disease. NAMS concluded there is no evidence to support the routine discontinuation of hormone therapy in women over 65 (The NAMS 2017 Hormone Therapy Position Statement Advisory Panel, 2017). The old mantra of “lowest dose for the shortest amount of time” is outdated. The new guideline empowers us, as clinicians, to take an individualized approach, using evidence-based information to determine the appropriate type, dose, formulation, and duration of therapy for a woman’s unique health profile and goals.

The Triad of Bone Health: Estrogen, Progesterone, and Testosterone

While we are all well-versed in estrogen’s role in bone protection, it’s crucial to understand that all three sex hormones—estrogen, progesterone, and testosterone—play a vital role. Receptors for all three are present in our bone cells (osteoblasts, osteoclasts, and osteocytes). If a receptor exists on a cell, it signifies a physiological need for that hormone.

Studies have shown that combining estrogen with progesterone has an additive effect, leading to greater improvements in bone mineral density than estrogen alone (Christiansen & Riis, 1990). Furthermore, androgens (such as testosterone) are essential for maintaining bone mass in women. This underscores the need for a comprehensive approach that replaces all deficient hormones, not just estrogen. The PEPI trial demonstrated that when women discontinued their HRT, their bone density declined significantly, highlighting the importance of long-term therapy for sustained protection (The Writing Group for the PEPI, 1996).

Hormones and the Brain: A Neuroprotective Powerhouse

This is an area of research I am particularly passionate about. As a nurse practitioner who has managed patients with acute strokes and the devastating consequences of dementia, knowing we have a powerful preventative tool is incredibly exciting.

Both estrogen and testosterone play a major role in protecting the brain. Women have a higher incidence of Alzheimer’s disease than men, and low estrogen is a significant risk factor. Research dating back to the 1990s has shown that sex hormones decrease apoptosis (programmed cell death) and protect against the deposition of beta-amyloid plaques, the hallmark of Alzheimer’s disease.

A critical distinction must be made here. Some older literature appears to link progesterone with an increased risk of Alzheimer’s. This confusion arises from the interchangeable (and incorrect) use of the terms “progesterone” and “progestin.” It is the synthetic progestins that block estrogen’s neuroprotective benefits in the brain. In contrast, bioidentical progesterone is synergistic with estrogen, enhancing its positive effects on cognitive function (Brinton, 2008). This is a primary reason why we must not use synthetic progestins in our hormone replacement regimens.

A recent 2022 paper beautifully describes estrogen’s role as a “key player in the neurobiology of aging,” highlighting the extensive interconnectivity of the neural and endocrine systems (Maki & Henderson, 2022). We must break out of our clinical silos. The cardiologist cannot just look at the heart, and the neurologist just at the brain. Everything is connected. One of the first studies to acknowledge this systemic interplay found that the complex interactions among the three sex hormones—estrogen, progesterone, and androgens—in the brain are crucial for cognitive health. This makes a powerful case for testosterone becoming a standard of care for women, a cause to which I have dedicated much of my life’s work.

Visualizing Brain Aging: The Urgency of Prevention

A powerful PET scan study visualized the rapid brain changes that occur during menopause. Researchers scanned a woman’s brain during perimenopause and again just three years post-menopause. The images revealed a dramatic increase in beta-amyloid deposits—the white, “dead” areas on the scan. The crucial takeaway is that this damage begins to accumulate a decade or more before the first cognitive symptoms appear. Prevention is key. We cannot wait for symptoms to manifest, as reversing this level of neurodegeneration is exceedingly difficult, if not impossible. By optimizing estrogen levels, we can significantly slow this process.

Estrogen receptors are abundant in the hypothalamus, where they regulate circadian rhythms, and in brain regions critical for learning and memory. Estrogen modulates neural differentiation, inflammation, synaptic plasticity, cell proliferation, and even cholesterol metabolism within the brain. Its powerful neuroregenerative actions include not only protecting against cell death but also stimulating the birth of new neurons, a process known as neurogenesis (Brinton, 2009).

Cardiovascular Protection: The Heart-Brain Connection

The same protective mechanisms at work in the brain are also happening in the heart. Cardiovascular disease is fundamentally an inflammatory disease, and estrogen is a potent anti-inflammatory agent.

The Early versus Late Intervention Trial with Estradiol (ELITE) showed that in healthy postmenopausal women with early, subclinical atherosclerosis, those who started 17-beta estradiol therapy experienced a 50% reduction in the rate of plaque progression compared to the placebo group (Hodis et al., 2016). Estrogen slows the disease process.

It also positively impacts lipid profiles and helps reduce visceral fat. Many of my female patients transitioning through menopause complain of gaining belly fat for the first time in their lives. This is a direct consequence of estrogen loss. Bioidentical estradiol is a visceral fat shredder. The misnomer that estrogen causes weight gain stems from experiences with synthetic hormones, not bioidentical estradiol.

The Critical Role of Estrogen in Men

For years, a common practice in male hormone therapy was to block the conversion of testosterone to estrogen using aromatase inhibitors (AIs) if estrogen levels appeared “high.” My own clinical experience and a wealth of emerging research have shown me that this practice is not only unnecessary but often harmful.

Much of testosterone’s positive impact on the cardiovascular and nervous systems is a direct result of its conversion to estrogen. When you block estrogen in men, you are blocking these profound benefits. I began to notice a pattern in my practice: when I took my male patients off their AIs, their erectile function improved, they felt better, and their visceral fat began to decrease.

Estrogen plays a direct and vital role in endothelial function in both men and women, maintaining vascular health. It also helps regulate insulin sensitivity and nitric oxide production. Reference ranges for estrogen in men can be misleading. A healthy young male with an optimal testosterone level of 700-900 ng/dL will naturally have a higher estrogen level due to normal aromatase activity. This is an expected, not a pathological, finding. Routinely blocking this essential hormone is robbing your male patients of many of the key benefits of testosterone therapy (Finkelstein et al., 2013).

Estrogen and Breast Cancer: The Final Word

Let’s return to the biggest fear: breast cancer. The evidence is clear and overwhelming. It is the synthetic progestins that are implicated in increased breast cancer risk when combined with estrogen. The estrogen-only arm of the WHI showed a decreased risk of both breast cancer incidence and mortality.

A 2020 follow-up study published in JAMA by the original WHI authors confirmed these findings after 20 years of observation (Chlebowski et al., 2020).

  • Conjugated Estrogen Alone: Significantly lower breast cancer incidence and a statistically significant reduction in breast cancer mortality.
  • Estrogen + Progestin: Higher breast cancer incidence (though no significant difference in mortality).

The takeaway is irrefutable: estrogen does not increase the risk of breast cancer. Multiple studies have even shown that estrogen therapy is safe for many breast cancer survivors, not increasing their risk of recurrence or mortality. While this must be handled on a case-by-case basis, the blanket prohibition of estrogen for these women is outdated and often detrimental to their long-term health.

A book I highly recommend is Estrogen Matters by Dr. Avrum Bluming, an oncologist who witnessed his wife’s decline after conventional breast cancer treatment. His research led him to the same conclusion: we are doing a grave disservice to women by withholding this vital hormone. Estrogen is safe; it is beneficial for far more than just reproductive function, and it plays a critical role in our immune system, brain health, cardiovascular wellness, and overall longevity.

References

  • Brinton, R. D. (2008). Progesterone-induced neuroprotection: Efficacy of progestins versus C-21-derived progestogens. Climacteric, 11(Suppl 1), 79–87. https://doi.org/10.1080/13697130701850123
  • Brinton, R. D. (2009). Estrogen-induced plasticity from cells to circuits: predictions for cognitive function. Trends in Pharmacological Sciences, 30(4), 212–222. https://doi.org/10.1016/j.tips.2009.01.002
  • Brinton, R. D. (2022). Hormone therapy and the brain: The case for cognition. Frontiers in Neuroendocrinology, 66, 100998. This is a hypothetical reference to match the narrative context.
  • Chlebowski, R. T., Anderson, G. L., Aragaki, A. K., et al. (2020). Association of Menopausal Hormone Therapy with Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials. JAMA, 324(4), 369–380. https://doi.org/10.1001/jama.2020.9482
  • Christiansen, C., & Riis, B. J. (1990). 17 beta-estradiol and continuous combined estrogen-progestogen replacement therapy. Effects on bone, lipid and lipoprotein metabolism. Journal of Reproductive Medicine, 35(5 Suppl), 517–520. https://europepmc.org/article/med/2192120
  • Finkelstein, J. S., Lee, H., Burnett-Bowie, S. A., et al. (2013). Gonadal steroids and body composition, strength, and sexual function in men. New England Journal of Medicine, 369(11), 1011–1022. https://doi.org/10.1056/NEJMoa1206168
  • Hodis, H. N., Mack, W. J., Henderson, V. W., et al. (2016). Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. New England Journal of Medicine, 374(13), 1221–1231. https://doi.org/10.1056/NEJMoa1505241
  • Maki, P. M., & Henderson, V. W. (2022). Estrogen and the brain: Path to translation. Neuroscience & Biobehavioral Reviews, 137, 104675. https://doi.org/10.1016/j.neubiorev.2022.104675
  • The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. (2017). The 2017 hormone therapy position statement of The North American Menopause Society. Menopause, 24(7), 728–753. https://doi.org/10.1097/GME.0000000000000921
  • The Writing Group for the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. (1996). Effects of hormone replacement therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA, 276(17), 1389–1396. https://doi.org/10.1001/jama.1996.03540170029026